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ABSTRACT 
 
SURFACE POLYSACCHARIDES PROMOTE INNATE IMMUNE EVASION BY  
THE PEDIATRIC PATHOGEN KINGELLA KINGAE   
Vanessa Lynne Muñoz 
Joseph W. St. Geme, III, M.D. 
 
The gram-negative coccobacillus Kingella kingae is an emerging pediatric 
pathogen and is increasingly recognized as a common etiological agent of osteoarticular 
infections and bacteremia in young children. The pathogenesis of K. kingae disease 
involves colonization of the posterior pharynx, invasion into the bloodstream, and 
dissemination to distant sites of infection. Previous studies have revealed that K. kingae 
produces a number of surface factors that may contribute to the pathogenic process, 
including a polysaccharide capsule and an exopolysaccharide. The purpose of this work 
was to determine the role of the K. kingae polysaccharide capsule and exopolysaccharide 
in promoting resistance to complement-mediated and neutrophil-mediated killing.  
 We determined that both the K. kingae capsule and exopolysaccharide prevented 
efficient binding of IgG, IgM, C4b, and C3b to the bacterial surface and inhibited 
complement-mediated killing. Abrogation of the classical complement pathway using 
EGTA-treated human serum restored survival of capsule-deficient, exopolysaccharide-
deficient K. kingae to wild-type levels, demonstrating that capsule and exopolysaccharide 
promote resistance to the classical complement pathway. Consistent with these results, the 
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capsule and exopolysaccharide enhanced K. kingae pathogenicity in juvenile rats with an 
intact complement system. Loss of the capsule and the exopolysaccharide resulted in 
avirulence, however not in rats lacking complement.  
Experiments using primary human neutrophils and a series of isogenic K. kingae 
mutants demonstrated the critical role of the capsule and the conditional role of the 
exopolysaccharide in preventing the neutrophil oxidative burst response and neutrophil-
mediated killing of K. kingae. In the absence of capsule, the exopolysaccharide prevented 
K. kingae opsonization and subsequently, reduced ROS production. The loss of capsule 
promoted neutrophil binding of K. kingae but had no effect on neutrophil phagocytosis and 
bacterial internalization of K. kingae. In contrast, the exopolysaccharide efficiently blocked 
neutrophil phagocytosis of K. kingae and resisted the bactericidal effects of antimicrobial 
peptides.  
This works establishes that the K. kingae surface polysaccharides are multi-
functional and play a critical role in K. kingae pathogenicity, facilitating evasion of host 
immunity. Our studies suggest that the K. kingae capsule and exopolysaccharide have 
potential as targets for vaccine development. 
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1. Introduction 
1.1 Kingella kingae history and pathogenicity 
Kingella kingae was first isolated in the 1960’s by Elizabeth O. King at the Centers 
for Disease Control in Atlanta, GA (Bovre, 1976; Henriksen & Bovre, 1968). The species 
belongs to the Neisseriaceae family under the Kingella genus, along with K. denitrificans, 
K. oralis, K. negevensis, and K. potus (Bovre, 1976; C. Chen, 1996; El Houmami et al., 
2017; Lawson et al., 2005; Maccato, McLean, Riddle, & Faro, 1991). K. kingae is a beta-
hemolytic gram-negative coccobacillus and is most often isolated from human respiratory 
secretions and from systemic sites in patients with bacteremia, endocarditis, osteomyelitis, 
or septic arthritis (Henriksen & Bovre, 1968). The organism can be recovered from the 
human oropharynx as a part of the oral commensal flora and primarily colonizes children 
between the ages of 6 and 36 months (Amit, Dagan, & Yagupsky, 2013; Yagupsky, Porat, 
& Pinco, 2009).  
As an emerging pediatric pathogen, K. kingae is increasingly recognized as the 
primary etiology of osteoarticular infections, a common etiology of bacteremia, and an 
occasional etiology of endocarditis in young children (Chometon et al., 2007b; Yagupsky, 
2014; Yagupsky, Erlich, Ariela, Trefler, & Porat, 2006; Yagupsky, Porsch, & St Geme III, 
2011). Invasive K. kingae disease is frequently associated with a concurrent viral 
respiratory infection in patients (J Amir & Yagupsky, 1998; Kiang et al., 2005; Seña, Seed, 
Nicholson, Joyce, & Cunningham, 2010; Yagupsky, 2004; Yagupsky & Dagan, 1994). 
Typically, patients under four years of age with invasive K. kingae disease are healthy, 
whereas older patients often have underlying health issues, including immunosuppression 
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or cardiac valve pathology (Dubnov-Raz et al., 2008, 2010; Yagupsky, 2004). The rate of 
K. kingae colonization in the oropharynx peaks between 12- to 24-months of age and 
steadily decreases as the child ages (Yagupsky, Dagan, Prajgrod, & Merires, 1995; 
Yagupsky, Peled, & Katz, 2002). This age-related pattern of colonization correlates with 
the development of the adaptive immune response against K. kingae (Yagupsky et al., 
1995, 2002). Asymptomatic colonization of the oropharynx is considered an immunizing 
event due to the increase in K. kingae cross-reactive antibody levels in older children and 
adults regardless of whether the child presents with invasive K. kingae disease (Slonim, 
Steiner, & Yagupsky, 2003; Yagupsky et al., 2011).  
Oropharyngeal colonization by K. kingae presumably begins with adherence to 
respiratory epithelial cells. In vitro studies demonstrate that adherence to human epithelial 
cells is mediated by two identified adhesins in K. kingae, type IV pili and the 
autotransporter protein Knh (Kehl-Fie et al., 2010; Kehl-Fie, Miller, & St. Geme, 2008; 
Kehl-Fie, Porsch, Miller, & St. Geme III, 2009; Porsch, Kehl-Fie, & St. Geme III, 2012). 
K. kingae interaction with epithelial cells is initiated by initial low-affinity adherence 
through type IV pili engagement with host receptors (Kern, Porsch, & St. Geme, 2017; 
Porsch et al., 2012). Subsequently, pili binding and retraction results in polysaccharide 
capsule displacement and Knh-mediated high-affinity adherence (Kern et al., 2017; Porsch 
et al., 2012).  
K. kingae type IV pili are comprised of the major pilin subunit, PilA1, and two 
minor pilus-associated proteins, PilC1 and PilC2 (Kehl-Fie et al., 2008; Porsch et al., 
2013). The PilA1 protein in K. kingae is homologous to other major type IV pilins found 
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in pathogens such as Neisseria meningitidis and Neisseria gonorrhoeae. Deletion of pilA1 
in K. kingae renders the bacterium nonpiliated and unable to adhere to epithelial cells or 
undergo twitching motility (pilus-dependent extension and retraction) in vitro (Kehl-Fie et 
al., 2008; Porsch et al., 2012). PilA1 expression is regulated by the PilS and PilR two-
component system and sigma factor s54; elimination of PilR and s54 results in a drastic loss 
of piliation whereas elimination of PilS only slightly affects piliation (Kehl-Fie et al., 
2009). Further examination of the pilin-encoding region of K. kingae determined that pilA1 
is transcribed upstream of two pilin-like genes, pilA2 and fimB (Kehl-Fie et al., 2008). 
However, transcriptional analysis and transmission electron micrographs demonstrated 
that in-frame deletions of pilA2 and fimB did not alter K. kingae piliation or adherence (the 
function of these two pilin-like genes remains unknown) (Kehl-Fie et al., 2008). The two 
minor pilus-associated proteins, PilC1 and PilC2, are encoded elsewhere in the genome 
and are homologous to the N. meningitidis and N. gonorrhoeae PilC proteins and the 
Pseudomonas aeruginosa PilY protein (Kehl-Fie et al., 2008; Porsch et al., 2013). 
Expression of either PilC1 or PilC2 promotes piliation, and deletion of both pilC1 and 
pilC2 results in a decrease of surface pili and loss of the adherence and twitching motility 
phenotype (Kehl-Fie et al., 2008; Porsch et al., 2013). Unlike the situation with mutations 
in PilR and s54, levels of PilA1 are not affected in the pilC1 and pilC2 double mutant, 
suggesting that the PilC proteins are either required or regulate pili assembly (Kehl-Fie et 
al., 2009; Porsch et al., 2013). The variability of K. kingae piliation across strains can be 
associated with the clinical site of isolation with most pharyngeal and bacteremia isolates, 
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expressing pili, while bone, joint, or endocarditis isolates generally being nonpiliated 
(Kehl-Fie et al., 2010, 2008).  
Knh (Kingella NhhA homolog) is a predicted 540 kDa trimeric autotransporter 
adhesin that forms short fibers on the K. kingae bacterial surface (Kern et al., 2017; Porsch 
et al., 2012). Elimination of Knh reduces, but does not completely abrogate K. kingae 
adherence to human epithelial cells (Porsch et al., 2012). Knh-mediated adherence is 
dependent on the retraction of type IV pili to displace the polysaccharide capsule and 
unmask Knh (Kern et al., 2017; Porsch et al., 2012). The inhibition of Knh-mediated 
adherence by capsule is suspected to be caused by the stark differences in Knh length and 
capsule depth, ~110 nm and ~700 nm, respectively (Kern et al., 2017). Similar to the 
HMW1/HMW2 adhesins of Haemophilus influenzae, Knh is N-glycosylated by an 
HMWC-like glycosyltransferase enzyme (Rempe et al., 2015). In the absence of 
glycosylation, Knh levels in the outer membrane are reduced and adherence to epithelial 
cells and autoaggregation is lost (Rempe et al., 2015). Annotation and analysis of the Knh 
amino acid sequence unveiled the presence of two predicted domains associated with 
adhesive activity, an ISneck2 domain located near the membrane anchor and multiple 
YadA-like head domains located near the N-terminus (Porsch et al., 2012). Regulation of 
Knh expression and the mechanism of presentation on the bacterial surface remains largely 
uncharacterized. However, preliminary data suggest that two genes immediately 
downstream of knh designated knhB and knhC may play a role in the presentation of Knh 
on the bacterial surface, as elimination of KnhB and KnhC slightly alters Knh-mediated 
adherence and autoaggregation of K. kingae (unpublished data).  
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Biofilm formation facilitates bacterial adherence and establishment of colonization 
in microbial communities. K. kingae cell-free extracts from biofilms exhibit broad-
spectrum anti-biofilm activity (Bendaoud et al., 2011). Examination of the K. kingae 
extracts determined the presence of two surface polysaccharides, the polysaccharide 
capsule and an exopolysaccharide (Bendaoud et al., 2011). The exopolysaccharide locus 
contains five genes (pamA, pamB, pamC, pamD, and pamE) and expression of pamABCDE 
or pamABC produces a galactan homopolymer (Bendaoud et al., 2011). Two unique 
exopolysaccharide structures have been identified so far (Bendaoud et al., 2011; Starr et 
al., 2013). Purified exopolysaccharide material, which is structually distinct from the 
polysaccharide capsule, prevents the biofilm formation of numerous microbes through 
surface physiochemical modifications (Bendaoud et al., 2011). Release of 
exopolysaccharide by K. kingae is speculated to enhance colonization by inhibiting biofilm 
formation of other commensal organisms and establishing its niche in the oropharynx. In 
an infant rat infection model, elimination of the exopolysaccharide attenuated K. kingae-
induced morbidity and mortality, suggesting that the exopolysaccharide plays a significant 
role in K. kingae virulence (Muñoz, Porsch, & St. Geme, 2018).  
Following asymptomatic colonization in the respiratory tract, K. kingae must 
breach the respiratory epithelium, enter the bloodstream, and spread to distant sites for 
disease progression (Amit et al., 2013; Bidet et al., 2013; Yagupsky et al., 2006, 2009). It 
is hypothesized that bloodstream invasion of K. kingae is facilitated by disruption of the 
respiratory epithelium due to viral co-infection and secretion of the K. kingae RtxA 
cytotoxin (Amit et al., 2012; Kehl-Fie & St. Geme III, 2007; Yagupsky et al., 2011). K. 
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kingae displays a wide range of cellular toxicity, and generation of a transposon mutant 
library identified the rtx locus as essential for cytotoxicity against epithelial, synovial, and 
macrophage-like cells in vitro (Kehl-Fie & St. Geme III, 2007). Furthermore, an RtxA-
deficient K. kingae mutant was associated with higher survival percentages and increased 
white blood cell counts when compared to wild type K. kingae in an infant rat infection 
model (Chang, Nudell, Lau, Zakharian, & Balashova, 2014). The rtx locus contains five 
genes (rtxB, rtxD, rtxA, rtxC, and tolC) necessary for the production and secretion of the 
RtxA toxin (Kehl-Fie & St. Geme III, 2007). Genetic analysis of the rtx locus and flanking 
regions suggests that the locus was acquired by K. kingae via horizontal transfer given the 
high homology to Moraxella bovis insertional elements and the M. bovis rtx locus (Kehl-
Fie & St. Geme III, 2007). RtxA is secreted by K. kingae through the type I secretion 
system (RtxB, RtxD, and TolC) and is present in cytotoxic and hemolytic outer membrane 
vesicles (Kehl-Fie & St. Geme III, 2007; Maldonado, Wei, Kachlany, Kazi, & Balashova, 
2011). RtxA induces cytotoxity through pore formation across planar lipid membranes; 
cation-selectivity of the RtxA channel induces a cation flux and programmed cell death 
(Bárcena-Uribarri, Benz, Winterhalter, Zakharian, & Balashova, 2015). Post-translational 
acylation of RtxA lysine residues and cholesterol binding are critical for the cytotoxic 
activity of RtxA (Osickova et al., 2018). 
Bacterial encapsulation provides a variety of benefits to microbes by allowing the 
organism to tolerate environmental stressors and evade host immunity during infection. K. 
kingae produces a polysaccharide capsule that enhances virulence in the infant rat infection 
model (Muñoz et al., 2018; Starr, Porsch, Seed, & St. Geme III, 2016). The polysaccharide 
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capsule in conjunction with the exopolysaccharide can protect K. kingae from complement-
mediated lysis by preventing opsonin deposition and complement activation (Muñoz et al., 
2018). In K. kingae, four distinct polysaccharide capsules (types a, b, c, and d) have been 
identified, with capsule types a and b accounting for greater than 95% of invasive disease 
isolates (Porsch, Starr, Yagupsky, & St. Geme III, 2017; Starr, Porsch, Seed, Heiss, et al., 
2016). Genetic analysis of K. kingae genomes revealed that clinical isolates contain one of 
four capsule-specific biosynthesis loci (csa, csb, csc, and csd), as well as a capsule export 
operon (ctrABCD) and capsule assembly genes (lipA and lipB) (Starr, Porsch, Seed, Heiss, 
et al., 2016; Starr, Porsch, Seed, & St. Geme III, 2016). Unlike the exopolysaccharide, the 
four K. kingae capsule types stain with cationic ferritin, which is consistent with anionic 
properties (Starr et al., 2013).  
As outlined, K. kingae expresses a number of surface or secreted factors that have 
been characterized as potential virulence factors necessary for K. kingae colonization and 
dissemination during pathogenesis (Table 1, Fig. 1).  
 
Table 1: K. kingae surface or secreted factors 
Factor Functions and comments 
Capsule - Protects against complement-mediated lysis, neutrophil 
activation and association, and antimicrobial peptides 
- Promotes virulence in vivo  
  
Exopolysaccharide - Protects against complement-mediated lysis, neutrophil 
phagocytosis, and antimicrobial peptides 
- Inhibits biofilm production of other microbes 
- Promotes virulence in vivo 
  
Knh - Promotes adherence to epithelial cells 
  
OMVs - Wide-spectrum cytoxicity 
- Contains RtxA, PilC2, and polysaccharide capsule 
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RtxA - Wide-spectrum cytoxicity 
- Promotes virulence in vivo 
  
Type IV pili - Promote adherence to epithelial cells, twitching motility, 
and natural competence  
- Contain PilC1 and PilC2 
*OMVs, outer membrane vesicles 
 
 
Figure 1: Diagram of K. kingae virulence factors. 
 
K. kingae surface or secreted factors that are hypothesized to influence colonization 
(bottom) or dissemination (top).  
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1.2 Bacterial surface polysaccharides 
1.2.1 Lipopolysaccharides 
Gram-negative bacterial cell walls are multilayered barriers comprised of an inner 
membrane, an outer membrane, and a thin peptidoglycan layer within the periplasmic space 
between the two membranes. The bacterial outer membrane consists of phospholipids, 
lipoproteins, surface proteins, and lipopolysaccharides (LPS). For gram-negative bacteria, 
the outer membrane is an asymmetric bilayer, with LPS localizing to the outer leaflet 
(Funahara & Nikaido, 1980; Kamio & Nikaido, 1976; Mühlradt & Golecki, 1975). The 
LPS (also known as endotoxin) composition is characterized by three separate structural 
components: lipid A, a core oligosaccharide, and an O-antigen repeating polysaccharide. 
Lipid A has a N-acetylglucosamine backbone that is highly acylated. As a 
phospholipid, lipid A anchors LPS to the hydrophobic outer membrane (Raetz, 1990; Raetz 
& Whitfield, 2002; Rietschel et al., 1994). For the majority of gram-negative bacteria, lipid 
A is required for growth, stability, and maintenance of the outer membrane barrier 
(Galloway & Raetz, 1990; Onishi et al., 1996; M. Vaara, 1993). Lipid A is highly 
conserved across bacterial species, and due to this conservation, fragmented or released 
LPS can be detected at the picomolar level by the host immune system (Aderem & 
Ulevitch, 2000; Medzhitov & Janeway, 2000). Innate immune cells, such as macrophages 
and neutrophils, along with endothelial cells, express Toll-like receptor 4 (TLR4), which 
binds lipid A moieties to trigger downstream immune cell activation and the release of 
inflammatory mediators (Beutler & Cerami, 1988; Dinarello, 1991; Drake, Cheng, Chang, 
& Taylor, 1993; Hoshino et al., 1999; Poltorak et al., 1998). While productive immune 
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responses to LPS promote bacterial clearance, lipid A is considered responsible for the 
toxicity of LPS, and overproduction of inflammatory mediators systemically can lead to 
cellular damage and septic shock in the host (Parrillo, 1993; van Deuren, Brandtzaeg, & 
van der Meer, 2000).  
The core oligosaccharide in LPS can be segmented further into the inner core, 
which is proximal to lipid A, and the outer core, which attaches the O antigen (Raetz & 
Whitfield, 2002). The inner core of most LPS structures contains keto-deoxyoctulosonate 
(Kdo) residues and can be modified with phosphates, phosphorylcholine, or 
phosphorylethanolamine residues (Brade, Opal, Vogel, & Morrison, 1999; Raetz & 
Whitfield, 2002). Diversity in modifications of the inner core provides heterogeneity of the 
LPS inner core; however, the outer core displays increased structural diversity (Raetz & 
Whitfield, 2002). The structural diversity of the LPS outer core is thought to be shaped by 
environmental pressures. Despite variation, the structural composition of the core 
oligosaccharide remains largely conserved among species within the same genus or family 
(Raetz & Whitfield, 2002). Conservation of the LPS core suggests that the structure is 
essential for bacterial membrane stability and integrity (Raetz & Whitfield, 2002).  
Unlike lipid A and the core oligosaccharide, O-antigen polymers are vastly diverse 
even within a single species.  Differences in the O-antigen structural composition can be 
due to changes in the glycosidic linkages, monomers, branching patterns, and inclusion of 
noncarbohydrate components (Brade et al., 1999; Knirel’ & Kochetkov, 1994). 
Heterogeneity is also observed in the O-antigen chain length, and LPS visualization on a 
gel exhibits a laddering effect due to variations in extension and addition of O units (Raetz 
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& Whitfield, 2002). The O-antigen polysaccharide provides protection against a host of 
immune responses, and recognition of the O-antigen by immune components depends on 
the structure, abundance, and length of the O-antigen (Burns & Hull, 1998; Joiner, 1988; 
Weiss, Hutzler, & Kao, 1986). Moreover, a loss or shortening of the O-antigen can hinder 
bacterial colonization and/or virulence (Nesper et al., 2001; R. C. Sandlin et al., 1995; 
Robin C. Sandlin, Goldberg, & Maurelli, 1996; Van den Bosch, Manning, & Morona, 
1997). The extent of protection and virulence provided by the O-antigen varies drastically 
across strains due to the wide range of structural diversity.  
Many mucosal pathogens such as H. influenzae and N. meningitidis express solely 
the lipid A moiety and the core oligosaccharide, producing a lipooligosaccharide (LOS) 
that lacks the O-antigen (Raetz & Whitfield, 2002).  LOS is also found in the outer leaflet 
of the outer membrane and has been demonstrated to mediate adherence and invasion of 
host cells in some species (Song, Ma, Chen, & Stein, 2000; van Vliet et al., 2009; Wetzler, 
Barry, Blake, & Gotschlich, 1992). Despite lacking the hypervariable O-antigen polymer, 
mucosal pathogens can adapt to immune and environmental pressures through phase 
variation prompting the expression of various forms of the LOS structure (Brade et al., 
1999; Giardina, Weiss, Gibson, & Apicella, 2001; Hood et al., 1999). The LOS core is 
comprised of an inner core that is often decorated with either mono- or oligosaccharide 
branches (considered the outer core), which are the determinants of antigenicity (Brade et 
al., 1999; Giardina et al., 2001; Hood et al., 1999). Sialylation and host-antigen mimicry 
of LOS structures promotes colonization and immune evasion by mucosal pathogens (R. 
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E. Mandrell et al., 1991; Robert E. Mandrell & Apicella, 1993; Moran, Prendergast, & 
Appelmelk, 1996).  
1.2.2 Polysaccharide capsules 
Capsular polysaccharides are lipidated, surface-anchored carbohydrate chains that 
contain multiple repeating saccharide units. Similar to the O-antigen present in LPS, 
capsules can consist of variations in sugar polymers, cyclic and isomer forms, and 
glycosidic linkages to generate unique antigenic epitopes within and across bacterial 
species. Polysaccharide capsules are generally considered anionic and highly hydrated, 
generating a mucoid-like phenotype (Gotschlich, Fraser, Nishimura, Robbins, & Liu, 
1981). While the capsule biosynthesis genes necessary for polysaccharide production tend 
to be genetically diverse, the export and assembly machinery remains highly conserved 
across encapsulated gram-negative bacteria (Whitfield, 2006; Whitfield & Roberts, 1999). 
For N. meningitidis, H. influenzae, and E. coli, a set of six conserved genes allow for 
polysaccharide capsule presentation (M Frosch, Edwards, Bousset, Krausse, & 
Weisgerber, 1991). Four of six conserved gene products form an ATP-binding cassette 
transporter system that facilitates proper export through ATP-hydrolysis and insertion of 
the polysaccharide capsule into the outer membrane (M. Frosch, Müller, Bousset, & 
Müller, 1992; Larue, Ford, Willis, & Whitfield, 2011; Pazzani et al., 1993). As the result 
of the highly selective pressure exerted by the immune system, polysaccharide diversity 
within a given species can be relatively high (e.g., E. coli, ~80 serotypes; N. meningitidis, 
13 serotypes; H. influenzae, 6 serotypes) (Cartwright, 1995; Moxon & Vaughn, 1981; 
Orskov, Orskov, Jann, & Jann, 1977; Whitfield, 2006). Interestingly, the pathogenicity of 
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a given pathogen can be dependent on the capsular type expressed, as certain capsules 
highly correlate with invasive disease, most notably the H. influenzae serotype b capsule 
(Cartwright, 1995; Moxon & Kroll, 1988; Moxon & Vaughn, 1981).  
Polysaccharide capsules are critical virulence factors for many microorganisms and 
have been widely shown to protect bacteria against mucosal and intravascular 
inflammatory immune responses (Campos et al., 2004; Lambris, Ricklin, & Geisbrecht, 
2008; Moxon & Vaughn, 1981; Nelson et al., 2007; Zwahlen, Kroll, Rubin, & Moxon, 
1989). The presence of capsule masks bacterial surface antigens recognized by antibodies 
or complement fragments. By preventing detection of these antigenic epitopes, capsules 
impede antibody and complement opsonization and thus efficiently protect the bacterium 
from complement-mediated lysis and neutrophil phagocytosis. Neutrophils have 
negatively charged surfaces, and therefore, expression of polysaccharide capsules 
increases electrostatic repulsion and reduces or prevents phagocytosis by enhancing the 
anionic properties of the bacterial surface (Jarvis & Vedros, 1987). Beyond physical 
hinderances, polysaccharide capsules can incorporate sialic acids into the repeating unit 
mimicking host moieties and effectively averting detection by the host immune system 
(Matthias Frosch & Maiden, 2006). Furthermore, sialic acid incorporation into the 
polysaccharide structure can recruit the complement regulatory protein, factor H (Meri & 
Pangburn, 1990; Schneider et al., 2006). Factor H acts on the complement alternative 
pathway by binding factor I, which cleaves complement fragment C3b into an inactive 
form, iC3b, and promotes decay of the C3 convertase, inhibiting the feedback loop of the 
alternative pathway.  
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Immunogenic studies performed in mice revealed a T-cell independent response to 
polysaccharide capsules during immunization (Barrett, 1985; A. Coutinho, Möller, 
Anderson, & Bullock, 1973; Antonio Coutinho & Möller, 1973). Due to the nature of the 
response, a lack of IgM to IgG class-switching during initial infection leads to inefficient 
antibody production and B-cell memory response upon re-challenge. To overcome the 
hallmark characteristics of a T-cell independent response, chemical conjugation of 
polysaccharide capsules to carrier proteins redirects the capsule to a T-cell dependent 
response and boosts capsule-specific memory B-cells, providing lasting immunity (Kelly 
et al., 2006; MacLennan et al., 2001). The polysaccharide capsules of S. pneumoniae, H. 
influenzae, and N. meningitidis have been extensively studied due to their importance as 
virulence factors and their effective use as polysaccharide-conjugate vaccines (Goldblatt, 
2000).  
1.2.3 Exopolysaccharides 
Exopolysaccharides are high molecular weight homo- or hetero-sugar polymers 
synthesized by bacteria and secreted into the extracellular milieu. Distinct characterization 
and clustering of exopolysaccharides can be difficult due to the heterogeneity across 
species, but polymers most commonly incorporate glucans, fructans, polygalactans, 
glucose, galactose, and rhamnose into the exopolysaccharide repeating unit (Gherardini & 
Helmer-Citterich, 2008; Ruas-Madiedo, Hugenholtz, & Zoon, 2002). The functionality of 
a given exopolysaccharide depends on the polymer structure, composition, and abundance.  
Bacterial exopolysaccharides have been studied primarily in relation to biofilms, 
specifically attributing to adherence, bacterial cell aggregation, water retention, nutrient 
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scavenging, and various other processes during biofilm formation and dispersal (Cerning, 
1991; De Vuyst & Degeest, 1999; Flemming, Neu, & Wozniak, 2007; Watnick & Kolter, 
2000). As a major contributor to the formation of biofilms, exopolysaccharides can provide 
scaffolding for the biofilm matrix and are necessary for adherence and cohesiveness during 
initial attachment to surfaces and microcolony establishment (Flemming & Wingender, 
2010; Rehm, 2010). Furthermore, differences in hydrophobicity of diverse 
exopolysaccharides can alter the biofilm architecture, stability, and storage of nutrients and 
enzymes (Nwodo, Green, & Okoh, 2012). While exopolysaccharide production is species-
specific, environmental factors such as temperature, pH, nutrient availability, and growth 
conditions can influence exopolysaccharide yield and biofilm formation (Looijesteijn, van 
Casteren, Tuinier, Doeswijk-Voragen, & Hugenholtz, 2000).    
 Exopolysaccharides produced by pathogens such as Pseudomonas aeruginosa, 
extraintestinal pathogenic E. coli, and Bordetella pertussis promote pathogenesis beyond 
biofilm formation through evasion of cellular and humoral innate immune components 
(Ganguly, Johnson, Kock, Parks, & Deora, 2014; Jones & Wozniak, 2017; Miajlovic, 
Cooke, Moran, Rogers, & Smith, 2014; Mishra et al., 2012). Despite lacking a membrane-
anchor, these exopolysaccharides exhibit similar properties to bacterial polysaccharide 
capsules by providing protection against neutrophil and complement activation and 
decreasing sensitivity to antimicrobial peptides and reactive oxygen species. Moreover, 
exopolysaccharides have also been demonstrated to interact with immune cells and can 
stimulate or dampen inflammatory responses during infection (Jones & Wozniak, 2017; 
Totté et al., 2015).  
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 Various bacterial exopolysaccharides exhibit advantageous properties such as high 
viscosity, gelling capacity, tensile strength, stability, and low solubility (Nwodo et al., 
2012). Synthetically polymerized exopolysaccharides, which can be valuable biomaterials, 
are frequently used for commercial and medical purposes. Common exopolysaccharides 
used in the food, petroleum, and pharmaceutical industries are alginate, cellulose, dextran, 
and xanthan (Nwodo et al., 2012). Several distinct forms of alginate are effective in the 
treatment of thromboembolic disorders due to the therapeutic characteristics, including 
anti-angiogenesis and anticoagulation (Alban, 2002). Xanthan gum has been utilized for a 
broad spectrum of diverse applications not limited to oil drilling, pesticides, and aqueous 
systems (Nwodo et al., 2012; Rosalam & England, 2006). 
1.2.4 K. kingae surface polysaccharides  
 Analysis of an Israeli collection containing over 400 K. kingae clinical isolates from 
invasive disease and asymptomatic carriers revealed that greater than 99% of isolates 
screened were encapsulated (Starr, Porsch, Seed, Heiss, et al., 2016). PCR amplification 
revealed four distinct amplicons in the capsule synthesis locus (Starr, Porsch, Seed, Heiss, 
et al., 2016).  Nucleotide sequencing revealed four unique loci, with one locus containing 
a single gene and three of the loci containing three genes (csaA, csbABC, cscABC, and 
csdABC) (Starr, Porsch, Seed, Heiss, et al., 2016). The capsule loci nomenclature was 
designated based on the type of capsule produced (e.g., csaA, capsule synthesis 
type a gene A) (Starr, Porsch, Seed, Heiss, et al., 2016; Starr, Porsch, Seed, & St. Geme 
III, 2016). Structural analyses were performed for purified capsule material from 12 K. 
kingae strains expressing one of the four capsule loci. The analysis revealed the distinct 
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polymer composition and linkages of the four capsule types (type a, [3)-β-GalpNAc-
(1→5)-β-Kdop-(2→]; type b, [6)-α-D-GlcpNAc-(1→5)-β-(8-OAc)Kdop-(2→]; type c, 
[3)-β-D-Ribf-(1→2)-β-D-Ribf-(1→2)-β-D-Ribf-(1→4)-β-Kdop-(2→]; and type d, [P-
(O→3)[β-D-Galp-(1→4)]-β-D-GlcpNAc-(1→3)-α-D-GlcpNAc-1-]) (Fig. 2) (Starr, 
Porsch, Seed, Heiss, et al., 2016). Within the Israeli K. kingae collection, 239 strains were 
isolated from healthy carriers and 178 strains were isolated from K. kingae infections 
(Starr, Porsch, Seed, Heiss, et al., 2016). Capsule typing revealed that greater than 95% of 
invasive isolates expressed either a type a or type b capsule; in comparison, 68% of carrier 
isolates expressed either a type a or type b capsule (Starr, Porsch, Seed, Heiss, et al., 2016). 
Types c and d represented 12% and 20% of carrier isolates, respectively; these percentages 
dropped to a combined 4% representation in the invasive isolates (Starr, Porsch, Seed, 
Heiss, et al., 2016). The distribution of capsule types in invasive versus carrier isolates was 
further validated by applying a multiplex PCR approach to an international collection of 
K. kingae clinical isolates (Porsch et al., 2017).    
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Figure 2: Structure of the polysaccharide capsules and exopolysaccharide types 
present in K. kingae clinical isolates. 
 
The polysaccharide capsule repeating unit structures (top panel) and the 
exopolysaccharide repeating unit structures (bottom panel). Top panel: capsule type 
a (A, GalNAc-Kdo), capsule type b (B, GlcNAc-Kdo), capsule type c (C, ribose-Kdo), 
and capsule type d (D, galacose-GlcNAc). Bottom panel: exopolysaccharide type 1 (1, 
galactan monosaccharide) and exopolysaccharide type 2 (2, galactan disaccharide). 
Adapted from (Starr et al., 2013) and (Starr, Porsch, Seed, Heiss, et al., 2016).  
 
 
Studies performed with K. kingae strain KK01, which expresses a type a capsule, 
demonstrated that capsule expression was necessary for full virulence in an infant rat 
infection model (Muñoz et al., 2018; Starr, Porsch, Seed, & St. Geme III, 2016). 
Furthermore, due to the depth of the polysaccharide capsule, surface antigens, including 
the autotransporter adhesin, Knh, present on the bacterial surface are masked. Masking of 
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these surface epitopes enhances survival of K. kingae in the presence of serum and 
modulates K. kingae adherence to epithelial cells (Kern et al., 2017; Muñoz et al., 2018; 
Porsch et al., 2012). 
Gas chromatography and nuclear magnetic resonance determined the glycosyl 
structure of surface polysaccharides from invasive K. kingae strains, KK01 and PYKK181 
(Bendaoud et al., 2011; Starr et al., 2013). Analysis determined that in addition to the 
polysaccharide capsule, strain KK01 produces a →5)-β-Galf-(1→ exopolysaccharide and 
strain PYKK181 produces a →3)-β-Galf-(1→6)-β-Galf-(1→ exopolysaccharide (Fig. 2) 
(Bendaoud et al., 2011; Starr et al., 2013). Both exopolysaccharides are linear galactan 
homopolymer exopolysaccharides with distinct glycosyl linkages (Bendaoud et al., 2011; 
Starr et al., 2013). The KK01 and PYKK181 exopolysaccharides were designated as type 
1 and type 2, respectively (Fig. 2). As previously mentioned in Ch. 1.1, expression of the 
type 2 exopolysaccharide from K. kingae or from an inducible plasmid in E. coli 
demonstrated that the exopolysaccharide exerted potent anti-biofilm properties inhibiting 
biofilm formation by gram-negative and gram-positive bacteria, as well as the fungal 
pathogen, Candida albicans (Bendaoud et al., 2011). In vivo juvenile rat studies using 
derivatives of strain KK01 demonstrated that the type 1 exopolysaccharide was necessary 
for full K. kingae virulence (Muñoz et al., 2018).  
 So far, there are no current publications identifying LPS genes or loci present in the 
K. kingae genome. Likewise, chemical or structural composition analyses of the K. kingae 
LPS, or more likely LOS, in clinical isolates has not been performed. Current ongoing 
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studies aim to address these critical gaps in knowledge in the attempt to broaden the 
understanding of K. kingae surface polysaccharides and involvement in pathogenesis.  
1.3 Innate immunity 
The immune system functions to protect the host against a variety of disease states, 
including invasion by microbial pathogens. Broadly, immunity can be divided into two 
main branches: innate immunity and adaptive immunity. Innate immunity is considered a 
non-specific, general response to foreign bodies, whereas adaptive immunity is considered 
a specialized, targeted response to specific antigens. Children rely heavily on the protective 
advantages of the innate immune system, as the adaptive immunity fully develops during 
childhood (Janeway, Travers, Walport, & Shlomchik, 2001). While innate immunity is 
composed of multiple cellular and humoral components, two key players are neutrophils 
and the complement system.  
1.3.1 Neutrophils  
 Neutrophils are the most abundant leukocyte (50-70%) present in human blood 
(Döhrmann, Cole, & Nizet, 2016). Human neutrophils are characterized by their segmented 
nucleus and the presence of multiple cytoplasmic vesicles (Borregaard, 2010). Generated 
in the bone marrow, terminally-differentiated neutrophils circulate in the bloodstream and 
are considered the first line of cellular defense during infection. Macrophages, mast cells, 
and complement recruit neutrophils to the site of inflammation by releasing 
chemoattractants (e.g., C5a, interleukin 8 (IL-8), and monocyte chemotactic factor), 
promoting expression of endothelial-leukocyte adhesive molecules (e.g., P- and E-selectins 
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and integrin CD11b/CD18) and increasing cell permeability (Kolaczkowska & Kubes, 
2013; Phillipson & Kubes, 2011). Upon recruitment and extravasation, activated 
neutrophils contain an arsenal of anti-microbial mechanisms to effectively combat 
infection.  
 As phagocytic cells, neutrophils bind and engulf microbes through the expression 
of surface receptors that recognize opsonins and foreign surfaces (Borregaard, 2010; 
Phillipson & Kubes, 2011). After phagocytosis, phagocytic vacuoles fuse with lysosomes 
to form mature phagolysosomes, and neutrophils utilize both oxidative and non-oxidative 
methods for optimal killing of engulfed bacteria (Borregaard, 2010; Falloon & Gallin, 
1986). Membrane-associated NADPH oxidases generate reactive oxygen species that are 
either released into the extracellular milieu or into phagolysosomes to target both 
intracellular and extracellular bacteria for oxidative killing (Borregaard, 2010; Nauseef, 
2007). Moreover, phagolysosomes fuse with granules for the release of antimicrobial 
peptides and proteases, including elastase, myeloperoxidase, defensins, and cathepsin G, 
to enhance bacterial killing inside the vacuoles (Falloon & Gallin, 1986). The release of 
cytotoxic and antimicrobial proteins into the extracellular milieu can also occur through a 
cellular process termed degranulation. During neutrophil maturation, three distinct types 
of granules are formed (azurophilic, specific, and tertiary) and are ultimately exocytosed 
as a consequence of neutrophil activation by inflammatory stimuli during infection 
(Borregaard, 2010; Falloon & Gallin, 1986). Degranulation also promotes recruitment of 
adaptive immune cells by enhancing lymphocytic infiltration through chemokine release 
(Nathan, 2006; Tecchio, Micheletti, & Cassatella, 2014).  
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 Lastly, neutrophils can undergo the release of neutrophil extracellular traps (NETs), 
which are primarily composed of DNA bound to histones, enzymes, and antimicrobial 
peptides (Brinkmann et al., 2004). NETs form a ‘sticky’ matrix immobilizing extracellular 
bacteria from further dissemination and aiding in phagocytosis (Papayannopoulos & 
Zychlinsky, 2009; Phillipson & Kubes, 2011). Trapped pathogens can also be directly 
killed by the densely concentrated, chromatin-associated antimicrobial proteins and 
peptides (Brinkmann et al., 2004).   
1.3.2 Complement 
Complement, a multifunctional group of proteins present in the blood and on cell 
surfaces, is a highly regulated component of the innate immune system. Complement 
activation promotes the recruitment of immune cells and recognition of pathogens through 
chemotaxis and opsonization (Gros, Milder, & Janssen, 2008). Complement is activated 
via three separate pathways: classical, lectin, and alternative. While activation of a distinct 
complement pathway is target-specific (antigen-antibody complexes—classical pathway, 
carbohydrate-lectin complexes—lectin pathway, and foreign surfaces—alternative 
pathway), all three pathways converge on the cleavage of C3 and the deposition of the 
protein fragment C3b on the target surface (Walport, 2001a, 2001b). C3b deposition 
promotes opsonization and formation of the membrane attack complex (MAC). MAC 
assembly, also known as the terminal pathway, is the sequential association of complement 
proteins, C5b, C6, C7, C8, and C9, which insert into the bacterial membrane to form a pore 
and mediate lysis of gram-negative bacteria (Bhakdi & Tranum-Jensen, 1988; Müller-
Eberhard, 1986). The cleavage of C3 and C5 leads to the release of anaphylatoxins, C3a 
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and C5a, which induce inflammatory responses that promote recruitment of phagocytes to 
the site of infection (Lambris et al., 2008). Phagocytes, including neutrophils and 
macrophages, recognize opsonized pathogens through membrane-associated receptors 
(e.g., CR1-4 and FcR); recognition by receptors prompts phagocytosis and bacterial 
clearance (Zipfel & Skerka, 2009). 
Over 20 soluble and surface-associated regulators control aberrant complement 
activation and allow complement to discriminate between foreign and non-foreign cell 
surfaces. To protect host cells from complement activation during inflammation, 
complement regulators inhibit C3b deposition on ‘self’ cells or cleave deposited C3b to its 
inactive form to prevent further complement activation and deposition (Zipfel & Skerka, 
2009). Complement regulators can also target anaphylatoxins C3a and C5a for degradation 
to dampen release of inflammatory mediators and prevent unnecessary recruitment of 
immune cells (Mueller-Ortiz et al., 2009; Skidgel & Erdös, 2007). Complement regulation 
functions beyond immune surveillance and facilitates neuroprotection, cellular 
homeostasis, and removal of cellular debris (Ricklin, Hajishengallis, Yang, & Lambris, 
2010; Walport, 2001a, 2001b). Soluble regulators are generally categorized by the 
complement pathway targeted: classical and lectin pathways (C1 inhibitor and C4b-binding 
protein (C4BP)), alternative pathway (factor H and properdin), and terminal pathway 
(vitronectin and clusterin) (Blom, Villoutreix, & Dahlbäck, 2004a; Davis, Mejia, & Lu, 
2008; Hourcade, 2008; Józsi & Zipfel, 2008; Preissner & Seiffert, 1998; Schwarz et al., 
2008). Membrane-associated regulators, including CR1, CR2, DAF, CD46, and CD59, can 
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act on all three pathways of complement activation by inactivating C3 and C4 (Zipfel & 
Skerka, 2009).  
1.4 Bacterial immune evasion mechanisms 
 
Bacterial pathogens have developed a multitude of parallel mechanisms that serve 
to withstand environmental stressors, evade host immune defenses, and promote survival 
within a host. As the first line of host defense during infection, neutrophils and complement 
are common targets of bacterial evasion mechanisms (Fig. 3 and Fig. 4).  
1.4.1 Neutrophil evasion 
Recruitment 
Chemoattractants recruit neutrophils to the site of inflammation and promote 
expression of surface adhesins to allow for neutrophil extravasation across the endothelial 
layer. The family of staphylococcal superantigen-like proteins (SSLs) promotes bacterial 
survival by interfering with recruitment of neutrophils during infection (Thammavongsa, 
Kim, Missiakas, & Schneewind, 2015). SSL5 and SSL11 interact with P-selectin 
glycoprotein ligand 1 (PSGL1) on neutrophil surfaces to prevent neutrophil adherence and 
extravasation through the endothelium (Bestebroer et al., 2007; Chung et al., 2007). 
Furthermore, SSL5 binds G protein-coupled receptors to inhibit anaphylatoxin-mediated 
activation of neutrophils and proinflammatory chemokine release (Bestebroer et al., 2007, 
2009). Secretion of SSL3 and SSL10 avert neutrophil chemoattraction through association 
with lymphocyte receptors, TLR2 and CXCR4, respectively (Spaan, Surewaard, Nijland, 
& van Strijp, 2013; Yokoyama et al., 2012). Group A Streptococcus dampens neutrophil 
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recruitment through the expression of a membrane-anchored serine protease SpyCEP that 
degrades the chemokine IL-8 (Zinkernagel et al., 2008). Streptococcal secreted esterase 
(Sse) and C5a peptidase A (SCPA) are secreted by the organism and inactivate C5a and 
chemotactic platelet-activating factor to further suppress neutrophil recruitment (M. Liu et 
al., 2012; Terao, Yamaguchi, Hamada, & Kawabata, 2006).  
Phagocytosis 
 Neutrophils recognize antibodies, complement fragments, and pathogen associated 
molecular patterns through the expression of various surface receptors that promote 
neutrophil association and phagocytic uptake of bacterial invaders. Bacterial cytotoxins 
play an integral role in promoting resistance to neutrophil phagocytosis and enhance 
bacterial invasion. Staphylococcus aureus can escape neutrophil phagocytic vacuoles 
through the expression of leukocidin LukAB (DuMont et al., 2013). Group A 
Streptococcus produces streptolysin S (SLS) and streptolysin O (SLO) that initiate 
neutrophil apoptosis and hinder phagocytosis (Datta et al., 2005; Timmer et al., 2009). 
During pathogenesis, mutations in the two-component system, CovRS, up-regulate 
streptolysin O production and boost innate immune evasion by streptococci (Sumby, 
Whitney, Graviss, DeLeo, & Musser, 2006; M. J. Walker et al., 2007).  
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Figure 3: Neutrophil antimicrobial functions and bacterial evasion factors. 
 
Evasion factors expressed by pathogen bacteria that target neutrophil recruitment 
(A), phagocytosis (B), the oxidative burst response/degranulation (C), and neutrophil 
extracellular traps (NETs) (D). Adapted from (Serruto, Rappuoli, Scarselli, Gros, & 
Van Strijp, 2010) and (Criss & Seifert, 2012). 
 
 
Encapsulated pathogenic bacteria physically avoid phagocytosis by preventing 
opsonization and neutrophil recognition of surface antigens. Moreover, bacterial capsules 
expressed by pathogens, such as N. meningitidis, prevent phagocytosis by enhancing the 
anionic properties of the bacterial surface (Jarvis & Vedros, 1987). Group A Streptococcus 
produces a membrane-anchored M protein that binds complement regulators (factor H and 
C4BP) and blocks opsonization to remain undetected by neutrophils (Oehmcke, Shannon, 
Mörgelin, & Herwald, 2010).  
Oxidative burst and degranulation 
27 
 
 Neutrophils contain oxidative and non-oxidative methods to effectively target and 
kill intracellular and extracellular bacteria. N. gonnorhoeae porin and group A 
Streptococcus streptolysin O impair stimulation of the neutrophil oxidative burst response 
and suppress reactive oxygen species (ROS) generation (Uchiyama et al., 2015; Wetzler, 
Blake, Barry, & Gotschlich, 1992). Streptococcal and staphylococcal superoxide 
dismutases enzymatically detoxify neutrophil superoxides to prevent bacterial killing via 
ROS production (Henningham, Döhrmann, Nizet, & Cole, 2015; Karavolos, Horsburgh, 
Ingham, & Foster, 2003). S. aureus also synthesizes enzymes that protect the bacterium 
from nitrosative stress, hydrogen peroxide, and hydroxy radicals (Cosgrove et al., 2007; G. 
Y. Liu et al., 2005; Richardson, Libby, & Fang, 2008). 
 Bacterial resistance to neutrophil degranulation and the influx of antimicrobial 
peptides is mediated by the expression of proteinases and efflux pumps that target granular 
contents (Criss, Katz, & Seifert, 2009; Hagman et al., 1995; Stapels et al., 2014; Stohl, 
Criss, & Seifert, 2005). Enzymatic modifications of the S. aureus peptidoglycan layer and 
teichoic acids impede bactericidal activity of neutrophil antimicrobial peptides and 
secreted proteases (Bera, Herbert, Jakob, Vollmer, & Götz, 2005; Ernst & Peschel, 2011; 
Peschel et al., 1999). 
Neutrophil extracellular traps 
 NET formation is considered a last effort attempt to kill extracellular bacteria by 
entangling microbes in DNA meshwork, increasing proximity to antimicrobial peptides, 
and facilitating phagocytosis. DNase production by streptococcal and staphylococcal 
strains is a significant effector for NET dispersal and evasion (Berends et al., 2010; 
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Buchanan et al., 2006). Degradation of NETs prevents entrapment and bacterial killing via 
antimicrobial peptides or neutrophil phagocytosis. Beyond the release of nucleases, the S. 
pneumoniae polysaccharide capsule protects against the antimicrobial effects of NET 
expulsion by reducing DNA interaction (Wartha et al., 2007). As previously mentioned, 
the group A Streptococcus SpyCEP peptidase targets IL-8 for degradation (Zinkernagel et 
al., 2008). IL-8 chemokine secretion promotes NET production and bacterial clearance.  
1.4.2 Complement evasion 
 Complement activation relies on a cascade of events to deposit opsonins on the 
bacterial surface and promote formation of the membrane attack complex and/or 
recognition by phagocytes. Microbes express a host of proteins that interrupt or impede 
proper activation of complement to escape detection by the immune system (Fig. 4).  
 
 
Figure 4: The complement system and evasion strategies by pathogenic bacteria.  
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The three pathways of complement activation and selected bacterial evasion factors 
listed near their relevant complement targets. Adapted from (Serruto et al., 2010). 
 
 
Complement regulators 
Acquisition of complement regulators is a common strategy for complement 
evasion by bacterial pathogens, such as E. coli, N. meningitidis, H. influenzae, and S. 
pneumoniae (Hallström & Riesbeck, 2010; Kugelberg, Gollan, & Tang, 2008; Lambris et 
al., 2008; Thammavongsa et al., 2015). Soluble complement regulators (factor H, factor H-
like protein 1, and C4BP) are present in high concentrations in human serum, making them 
readily accessible for acquisition by invading microbes. Neisserial species express multiple 
and often redundant surface proteins or structures that interact with complement regulators 
to promote survival in the host. N. meningitidis produces factor H-binding proteins, NspA 
and fHbp, as well as the C4BP-binding protein PorA (Jarva, Ram, Vogel, Blom, & Meri, 
2005; Lewis et al., 2010; Lewis, Carter, & Ram, 2012; Madico et al., 2006); N. 
gonorrhoeae produces the factor H-binding protein PorB1A, which also binds C4BP along 
with PorB1B (Ram et al., 2001; Ram, McQuillen, et al., 1998). The sialylated LOS 
produced by N. gonorrhoeae has also been observed to interact with human factor H (Ram, 
Sharma, et al., 1998).  
Antigen masking 
Despite the vast diversity of polysaccharide capsule structures, bacterial 
encapsulation provides protection by masking surface antigens from antibody recognition 
and physically preventing complement deposition on the bacterial surfaces (Achtman, 
1995; Horwitz & Silverstein, 1980; Kugelberg et al., 2008; Peterson, Wilkinson, Kim, 
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Schmeling, & Quie, 1978). Similarly, N. meningitidis can evade antibody detection by 
mimicking host-cell surfaces with sialylated LOS and masking bacterial epitopes 
(Schneider, Exley, Ram, Sim, & Tang, 2007; van Vliet et al., 2009). 
Proteolytic degradation 
 The release of bacterial proteases or acquisition of host enzymes for antibody or 
complement degradation has been readily exploited by bacteria to prevent complement 
activation.  Pseudomonas species prevent activation of the classical complement pathway 
by inactivating or degrading immunoglobulins, C1q, and C3 to non-functional fragments 
by the elastase PaE and alkaline protease PaAP (Lambris et al., 2008; Rooijakkers & van 
Strijp, 2007). Group A and B streptococci express C5a peptidases that degrade C5a and 
halt chemotactic signaling and proinflammatory responses (Chmouryguina, Suvorov, 
Ferrieri, & Cleary, 1996). Furthermore, exotoxin B from S. pyrogenes targets complement 
regulator properdin for degradation, destabilizing C3 convertases deposited on bacterial 
surfaces (Tsao et al., 2006).  
Professional complement evader – Staphylococcus aureus 
Gram-positive bacteria passively inhibit MAC formation due to their thick 
peptidoglycan cell wall; however, gram-positive bacteria can still be opsonized by 
antibodies or complement fragments and targeted by phagocytic cells. Complement 
evasion by S. aureus has been extensively studied due to its vast array of surface factors 
that inhibit multiple complement pathways and regulators. In addition to many other 
complement-targeted staphylococcal proteins, S. aureus produces staphylococcal 
complement inhibitor (SCIN), which inhibits the alternative pathway C3 convertase to 
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prevent C3b opsonization and release of C3a and C5a (Rooijakkers, Ruyken, et al., 2005). 
Secreted proteins SSL7 and Sbi-I/Sbi-II bind to human immunoglobulins to interfere with 
antibody recognition and block activation of the classical complement pathway (H. K. Kim 
et al., 2012; Thammavongsa et al., 2015; Zhang, Jacobsson, Vasi, Lindberg, & Frykberg, 
1998). S. aureus expresses plasminogen kinase that binds and converts endogenous 
plasminogen into plasmin; on the bacterial surface, plasmin can degrade both IgG and C3 
(Lähteenmäki, Kuusela, & Korhonen, 2001; Rooijakkers, van Wamel, Ruyken, van Kessel, 
& van Strijp, 2005). Efb and Ecb are multi-functional staphylococcal proteins that disrupt 
the C3 and C5 convertases and bind C3d (a C3b cleavage product) and factor H to prevent 
complement activation and proinflammatory responses (Amdahl et al., 2013; H. Chen et 
al., 2010; Jongerius et al., 2007). 
1.5 Dissertation overview 
Chapter 2 describes how the K. kingae polysaccharide capsule and 
exopolysaccharide promote survival in the presence of human serum and active 
complement by preventing antibody and opsonin deposition. Additionally, Chapter 2 
demonstrates that both surface polysaccharides are necessary for full virulence of K. kingae 
in an infant rat infection model. Chapter 3 examines the distinct roles of the polysaccharide 
capsule and exopolysaccharide in protecting K. kingae against neutrophil-mediated killing. 
Chapter 4 delves into the characterization of the exopolysaccharide locus and determines 
the diversity of the exopolysaccharide in clinical isolates. Lastly, Chapter 5 summarizes 
the future directions and implications of this work.  
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2. Kingella kingae surface polysaccharides promote resistance to 
human serum and virulence in a juvenile rat model  
2.1 Introduction 
The encapsulated gram-negative coccobacillus Kingella kingae is a member of the 
commensal flora in the oropharynx in young children and is emerging as an important 
pathogen in the pediatric population (Yagupsky et al., 2009). Recent epidemiological 
studies using sensitive PCR-based diagnostics have revealed that K. kingae is a leading 
cause of osteoarticular infections in young children between 6 and 36 months of age 
(Chometon et al., 2007a; Yagupsky, 2014; Yagupsky et al., 2011).  In addition, K. kingae 
is a known cause of bacteremia and endocarditis in this population (Yagupsky, 2014; 
Yagupsky et al., 2011). Following asymptomatic colonization of the upper respiratory tract, 
K. kingae can breach the epithelium, enter the bloodstream, and spread to distant sites to 
produce disease (Amit et al., 2013; Bidet et al., 2013; Kehl-Fie & St. Geme III, 2007; 
Yagupsky et al., 2006, 2009). The mechanism by which K. kingae evades host innate 
immune responses during oropharyngeal colonization, in the bloodstream, and at sites of 
invasive disease is currently poorly understood. 
Survival of bacteria in the bloodstream involves a complex interplay between the 
organism and the innate and adaptive immune systems. The innate immune system 
provides a rapid and immediate response to infection and plays an especially important role 
in children, who have a relatively naïve adaptive immune system. A key component of 
innate immunity in the bloodstream is the complement system, a highly regulated and 
multifunctional group of circulating proteins that promote recognition of pathogens by 
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immune cells through chemotaxis and opsonization and that are capable of direct killing of 
bacteria (Ricklin et al., 2010; Sarma & Ward, 2011). Complement is activated via the 
classical, the alternative, and the lectin pathways; all three of these pathways converge on 
the deposition of the protein fragment C3b on the bacterial surface. C3b promotes 
opsonization and formation of the membrane attack complex (MAC), which mediates 
direct lysis of gram-negative bacteria (Ricklin et al., 2010; Sarma & Ward, 2011). Invasive 
bacterial pathogens express a variety of extracellular factors that mediate resistance to 
complement-mediated opsonin deposition and bacterial lysis.  
Bacterial pathogens commonly express surface polysaccharides, which serve a 
multitude of functions and often allow the organism to tolerate environmental stressors, 
evade host immune mechanisms, and ultimately survive within the host. Capsular 
polysaccharides are lipidated, surface-anchored carbohydrate chains that have been widely 
shown to protect bacteria against mucosal and intravascular inflammatory responses by 
preventing phagocytosis and complement-mediated lysis (Geoffroy, Floquet, Métais, 
Nassif, & Pelicic, 2003; Horwitz & Silverstein, 1980; Noel, Hoiseth, & Edelson, 1992; 
Peterson et al., 1978). The polysaccharide capsules of Streptococcus pneumoniae, 
Haemophilus influenzae, Neisseria meningitidis, and a variety of other organisms have 
been extensively studied due to their importance as virulence factors and their effective use 
as vaccine antigens (Goldblatt, 2000; Hyams, Camberlein, Cohen, Bax, & Brown, 2010; 
Moxon & Kroll, 1988; Swartley et al., 1997). In K. kingae, four distinct polysaccharide 
capsules have been identified, designated types a, b, c, and d (Starr, Porsch, Seed, Heiss, 
et al., 2016). Capsule types a and b account for greater than 95% of invasive disease isolates 
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(Porsch et al., 2017; Starr, Porsch, Seed, Heiss, et al., 2016). Previous work has 
demonstrated that the capsule is required for full K. kingae virulence in a juvenile rat model 
of invasive disease (Starr et al., 2013; Starr, Porsch, Seed, & St. Geme III, 2016).  
Bacteria can also express additional or alternative surface polysaccharides, known 
as exopolysaccharides, which are secreted carbohydrate polymers that are not covalently 
anchored to the bacterial membrane and hence are different from polysaccharide capsules 
(Nwodo et al., 2012; Sutherland, 1982). To date, exopolysaccharides have been studied 
largely in the context of bacterial biofilm formation and dispersal. In addition to expressing 
a capsular polysaccharide, K. kingae produces a galactofuranose homopolymer 
exopolysaccharide called the PAM galactan, which has been previously shown to have 
anti-biofilm properties (Bendaoud et al., 2011; Starr et al., 2013). While a number of 
bacterial polysaccharide capsules have been studied for their ability to promote evasion of 
complement-mediated and neutrophil-mediated killing, understanding of the role of 
exopolysaccharides in these functions is limited (Ganguly et al., 2014; Jones & Wozniak, 
2017; Miajlovic et al., 2014; Mishra et al., 2012).  
In this study, we found that K. kingae is highly resistant to serum killing, resulting 
from the overlapping ability of the polysaccharide capsule and the exopolysaccharide to 
prevent opsonin deposition and complement-mediated lysis via the classical pathway. 
Elimination of both the capsular polysaccharide and the exopolysaccharide resulted in a 
complete loss of virulence in juvenile rats, highlighting the critical roles of these surface 
polysaccharides in K. kingae virulence.  
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2.2 Methods 
2.2.1 Bacterial strains and growth conditions 
The strains used in this study are listed in Table 2. The parent K. kingae strain 269-
492 (Kehl-Fie & St. Geme III, 2007) grows on solid agar as two phenotypically stable 
colony types, designated KK01 and KK03.  As described in our earlier work, the KK01 
and KK03 colony types differ in their density of piliation.  K. kingae KK01 was used as 
the wild type strain throughout this study.  K. kingae strains were stored at -80°C in brain 
heart infusion (BHI) broth with 20% glycerol.  
E. coli strains were stored at -80°C in Luria-Bertani (LB) broth with 15% glycerol. 
K. kingae strains were grown at 37°C with 5% CO2 on chocolate agar plates supplemented 
with 50 µg/ml kanamycin or 1 µg/ml erythromycin, as appropriate. E. coli strains were 
grown at 37°C on LB agar or in LB broth supplemented with 100 µg/ml ampicillin, as 
appropriate.  
Table 2: Strains and plasmids used in this study 
Strain Description Reference 
Kingella kingae   
KK01 Nonspreading/noncorroding derivative of 
269-492 
(Kehl-Fie & St. 
Geme III, 2007) 
PYKK98 Clonal group B isolate from case of 
bacteremia, capsule type a 
Yagupsky, P.  
PYKK93 Clonal group P isolate from case of 
bacteremia, capsule type a 
Yagupsky, P.  
PYKK58 Clonal group N isolate from case of septic 
arthritis, capsule type b 
Yagupsky, P.  
KK146 Clonal group N isolate from case of 
bacteremia, capsule type b 
Yagupsky, P.  
PYKK060 Clonal group D isolate from case of 
endocarditis, capsule type c 
Yagupsky, P.  
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ATCC23330 Clonal group D isolate from a healthy 
carrier, capsule type c 
ATCC 
E3339 Clonal group F isolate from a healthy 
carrier, capsule type d 
Yagupsky, P.  
BB270 Clonal group U isolate from a healthy 
carrier, capsule type d  
Yagupsky, P.  
KK01csaA Contains csaA deletion (Starr, Porsch, 
Seed, & St. 
Geme III, 2016) 
KK01pam Contains pamABCDE deletion (Starr et al., 
2013) 
KK01csaApam Contains csaA deletion and pamABCDE 
deletion 
This study 
KK01SwapEmpty Contains the capsule synthesis locus 
flanking genes and a deletion of the csaA 
region 
(Starr, Porsch, 
Seed, Heiss, et 
al., 2016) 
KK01Swapcsa KK01SwapEmpty with csa locus 
recombined 
(Starr, Porsch, 
Seed, Heiss, et 
al., 2016) 
KK01Swapcsb KK01SwapEmpty with csb locus 
recombined 
(Starr, Porsch, 
Seed, Heiss, et 
al., 2016) 
KK01Swapcsc KK01SwapEmpty with csc locus 
recombined  
(Starr, Porsch, 
Seed, Heiss, et 
al., 2016) 
KK01Swapcsd KK01SwapEmpty with csd locus 
recombined 
(Starr, Porsch, 
Seed, Heiss, et 
al., 2016) 
KK01SwapEmptypam KK01SwapEmpty with pamABCDE 
deletion 
This study 
KK01Swapcsapam KK01Swapcsa with pamABCDE deletion This study 
KK01Swapcsbpam KK01Swapcsb with pamABCDE deletion This study 
KK01Swapcscpam KK01Swapcsc with pamABCDE deletion This study 
KK01Swapcsdpam KK01Swapcsd with pamABCDE deletion This study 
E. coli  
  
DH5a  E. coli F- φ80dlacZ∆M15 ∆(lacZYA-
argF)U169 deoR recA1 endA1 hsdR17(rK
- 
mK
+) phoA supE441 thi-1 gyrA96 relA1  
(Sambrook, 
Fritsch, & 
Maniatis, 1989) 
H. influenzae   
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C54 Haemophilus influenzae serotype b isolate (Pichichero, 
Loeb, Anderson, 
& Smith, 1982) 
C54 b-  Spontaneous capsule deficient derivative 
of strain C54 
(St. Geme & 
Falkow, 1991) 
Plasmid Description Reference 
E. coli  
  
pUC19pam::ermC pUC19 with ermC erythromycin cassette 
flanked by surrounding 5’ and 3’ regions 
of the pamABCDE locus 
(Starr et al., 
2013) 
2.2.2 Strain construction 
The csaA mutant, the pam mutant, and the capsule swap strains were generated as 
previously described (Starr et al., 2013; Starr, Porsch, Seed, Heiss, et al., 2016; Starr, 
Porsch, Seed, & St. Geme III, 2016). To generate the KK01csaApam double mutant and 
the capsule swap strains containing the pam locus deletion, strains KK01csaA, 
KK01Swapcsa, KK01Swapcsb, KK01Swabcsc, KK01Swapcsd, and KK01SwapEmpty 
were transformed with linearized plasmid pUC19pam::ermC. Briefly, the plasmid was 
purified from E. coli, linearized with NdeI, and introduced into the parental strains (csaA 
mutant or swap strains) via natural transformation. Transformants were recovered on 
chocolate agar plates containing 1.0 µg/ml erythromycin. Correct insertion of the gene 
disruption construct was confirmed via PCR and sequencing of the deletion site. The 
absence of capsule and exopolysaccharide was confirmed in strain KK01csaApam and the 
capsule swap pam deletion strains using Alcian blue and silver staining as previously 
described (Porsch et al., 2012; Starr et al., 2013), with the parental strains and strain KK01 
as controls.  
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2.2.3 Polysaccharide extraction and staining 
For capsule extractions, bacteria were washed and resuspended in Tris acetate pH 
5 for one hour. Cells were removed by centrifugation, and extracts were treated with 
proteinase K for one hour, and then concentrated as previously described (Porsch et al., 
2012). For exopolysaccharide extractions, bacteria were resuspended in 5 ml PBS and 
vortexed. Cells were removed by centrifugation, and bacterial supernatants were treated 
with proteinase K for one hour, and then concentrated as previously described (Porsch et 
al., 2012). 
Aliquots of supernatant and purified capsule from K. kingae derivatives were 
separated on 7.5% or 10% SDS-PAGE gels, respectively. For supernatant samples, SDS-
PAGE gels were treated first with silver staining and subsequently with Alcian blue 
staining. For purified capsule samples, SDS-PAGE gels were treated with Alcian blue 
staining. For silver staining, gels were treated as previously described (J. S. Kim, Reuhs, 
Rahman, Ridley, & Carlson, 1996). For Alcian blue staining, gels were stained with 
0.125% Alcian blue as previously described (Porsch et al., 2012).  
2.2.4 Serum bactericidal assays 
K. kingae strains and E. coli strain DH5a were grown on chocolate agar plates and 
then resuspended in PBS containing 0.1% gelatin (PBS-G). H. influenzae strains were 
grown on chocolate agar plates overnight, resuspended in BHI with 3.5 µg/ml NAD and 
0.1% lysed horse blood to an OD600 of 0.2, and were grown to an OD600 between 0.6-0.8 
shaking at 250 rpm. Samples were diluted in PBS-G to obtain a final inoculum of 
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approximately 4.0 x 103 cfu/0.1 ml. The respective inocula were mixed with pooled NHS 
(Immucor, Norcross, GA) or HI-NHS (prepared by incubating NHS at 56°C for 20 min) 
diluted in PBS-G, as appropriate, and incubated for various time points at 37°C with 5% 
CO2. Complement activity was assessed and confirmed using a total hemolytic assay as 
previously described (Costabile, 2010). Serial dilutions of the inoculum and reaction 
samples were plated on chocolate agar plates and incubated overnight at 37°C with 5% 
CO2 to determine cfu counts (limit of detection for plating: 20 cfu). To perform classical 
pathway inhibition assays, samples were incubated with EGTA at a final concentration of 
5 mM and supplemental MgCl2 at a final concentration of 9 mM prior to introduction of 
NHS. 
2.2.5 Flow cytometry analysis 
K. kingae strains were grown on chocolate agar plates, resuspended to an OD600 0.8 
in PBS, pelleted, and resuspended in 4% paraformaldehyde in PBS for fixation. After 
incubation for 20 min at room temperature (RT), bacteria were washed with Tris-buffered 
saline (TBS) and resuspended in PBS. We modified previously described protocols to 
detect bacterial opsoninization (Agarwal, Vasudhev, DeOliveira, & Ram, 2014; Mishra et 
al., 2012). Briefly, fixed bacteria were incubated with 20% NHS as the source of C3b or 
1% NHS as the source of C4b. Samples were incubated with gentle agitation for 15 min at 
RT, washed with PBS, and resuspended in TBS containing 50 mM EDTA and 0.1% bovine 
serum albumin (BSA). Fixed bacteria were incubated with or without a 1:250 dilution of a 
mouse anti-human C3b monoclonal antibody (Thermo Fisher, Rockford, IL) or a 1:250 
dilution of a rabbit anti-human C4b monoclonal antibody (Abcam, Cambridge, MA) for 1 
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hr at RT. Samples were washed twice in PBS, resuspended in PBS containing 0.1% BSA, 
and incubated with a 1:200 dilution of a rabbit anti-mouse IgG DyLight 488-conjugated 
antibody (Rockland, Limerick, PA) or a 1:200 dilution of a goat anti-rabbit IgG DyLight 
488-conjugated antibody (Rockland) for 45 min at RT as appropriate. Bacteria were 
washed, resuspended in PBS, and stained with propidium iodide (Biotium, Fremont, CA) 
for flow cytometry analysis. For classical pathway inhibition assays, samples were 
incubated with EGTA at a final concentration of 5 mM and supplemental MgCl2 at a final 
concentration of 9 mM prior to introduction of NHS. 
 For human IgG and human IgM surface deposition analysis, bacteria were fixed, 
resuspended in TBS containing 50 mM EDTA and 0.1% BSA, and then incubated with 
PBS as a control or 1% HI-NHS as a source of human IgG and human IgM. After gentle 
agitation for 1 hr at RT, samples were washed twice with PBS, resuspended in PBS 
containing 0.1% BSA, and then incubated with a 1:200 dilution of a goat anti-human IgG 
(H&L) DyLight 488-conjugated antibody (Rockland) or a 1:200 dilution of a goat anti-
human IgM (mu chain) DyLight 488-conjugated antibody (Rockland) for 45 min at RT. 
Bacteria were washed, resuspended in PBS, and stained with propidium iodide (Biotium) 
for flow cytometry analysis. Flow cytometry assays were performed using an Accuri C6 
instrument (BD Biosciences, San Jose, CA).  
2.2.6 K. kingae-specific serum antibody detection 
Serum antibodies reactive to K. kingae whole cell and outer membrane fractions 
were determined by Western blotting. Total membranes were recovered by centrifugation 
of cleared bacterial sonicates and outer membrane fractions were isolated on the basis of 
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sarkosyl insolubility. The whole cell and outer membrane fractions were separated on a 
7.5% SDS-PAGE gel, transferred to nitrocellulose, and probed with 2% HI-NHS, followed 
by an anti-human Ig– horseradish peroxidase (HRP)-conjugated secondary antibody 
(Sigma, St. Louis, MO) at a dilution of 1: 5,000. The blot was developed by using a 
chemiluminescent substrate.  
2.2.7 Juvenile rat infection model 
Nursing 5-day-old Sprague-Dawley rat pups (Charles River Laboratories, 
Wilmington, MA) were injected via the intraperitoneal route with 0.1 ml PBS alone 
(control) or 10 µg of CVF (Complement Technology, Tyler, TX) in 0.1 ml PBS. K. kingae 
strains were grown on chocolate agar for 18 hrs, and the bacteria were swabbed from plates 
and resuspended in PBS to a final density of 1 x 108 cfu/ 0.1 ml. While the in vitro serum 
bactericidal assays used 1 x 103 cfu to conserve human serum, 1 x 108 cfu was the necessary 
infectious dose in vivo to consistently generate invasive disease in rat pups with strain 
KK01. Three hours post-CVF injection, rat pups were injected via the intraperitoneal route 
with 0.1 ml of the appropriate bacterial suspension or 0.1 ml of PBS alone (control). Rat 
pups were injected using a 27 1/2-gauge needle and then returned to their cage with a 
lactating dam. The experimental and control groups were housed separately with a lactating 
dam and were monitored for mortality and signs of illness every six hours for the first 30 
hrs and then twice daily for a total of five days. Animals found to be moribund were 
euthanized by using CO2 inhalation followed by secondary decapitation.  
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2.2.8 Ethics statement 
All animal experiments described within were conducted in accordance with the 
Animal Welfare Act, the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals from the U.S. Department of Health and Human Services, and the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Research Council. The Children’s Hospital of Philadelphia animal research facilities have 
full accreditation from the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) International. The animal procedures were approved by the 
Children’s Hospital of Philadelphia Institutional Animal Care and Use Committee 
(IACUC) under protocol IAC 16-001050. 
2.2.9 Statistical analysis 
Statistical analyses were performed with GraphPad Prism version 7.0a for Mac 
(GraphPad Software, San Diego, CA) where P < 0.05 was considered statistically 
significant. Unpaired Student’s t-test was performed as appropriate. Mortality rates were 
calculated using the log-rank (Mantel-Cox) test for significance.  
2.3 Results 
2.3.1 K. kingae is highly resistant to complement-mediated lysis. 
The ability of K. kingae to survive in the bloodstream in young children suggests 
that the organism is capable of evading the host innate immune response. To test the 
capacity of K. kingae to evade complement-mediated lysis, we performed serum 
bactericidal assays using normal human serum (NHS) as a source of active complement or 
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heat-inactivated (HI)-NHS as a source of inactive complement. K. kingae strain KK01 at 
an inoculum of 1.0 x 103 cfu (colony forming units) was incubated for 1 hr with serum 
concentrations ranging from 2% to 50% (Fig. 5A), using E. coli strain DH5a as a serum-
sensitive control. To assess serum sensitivity, a survival ratio was calculated, dividing the 
number of cfu recovered from NHS by the number of cfu recovered from HI-NHS. The 
limit of detection for plating was 20 cfu, which enabled detection of up to a 98% reduction 
in bacterial survival. At low NHS concentrations, there was no killing of strain KK01 but 
complete killing of strain DH5a (Fig. 5A). At a NHS concentration of 50%, strain KK01 
had a survival ratio of approximately 0.80 (cfu in NHS divided by cfu in HI-NHS) (Fig. 
5A). As expected, HI-NHS had no effect on survival of strain KK01 or strain DH5a at any 
serum concentration. These results demonstrate that K. kingae exhibits high-level 
resistance to complement-mediated lysis. 
2.3.2 Surface polysaccharides prevent complement-mediated lysis of K. 
kingae. 
To determine the role of the K. kingae surface polysaccharides (the polysaccharide 
capsule and the exopolysaccharide) in serum resistance, we performed serum bactericidal 
assays using strain KK01 mutants deficient in expression of the polysaccharide capsule, 
the exopolysaccharide, or both, using strain KK01csaA (a capsule-deficient mutant lacking 
the csaA capsule synthesis gene) (Starr, Porsch, Seed, & St. Geme III, 2016), strain 
KK01pam (an exopolysaccharide-deficient mutant lacking the pamABCDE galactan 
exopolysaccharide synthesis operon) (Starr et al., 2013), and strain KK01csaApam (a 
double mutant lacking both capsule and exopolysaccharide synthesis genes). Serum 
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bactericidal assays were performed as described above using 50% serum for 1 hr and using 
E. coli strain DH5a as a serum-sensitive control. In addition, isogenic encapsulated and 
non-encapsulated derivatives of H. influenzae strain C54 (designated [+] for encapsulated 
and [–] for non-encapsulated strains) were included as controls to demonstrate the 
importance of the polysaccharide capsule in serum resistance for another gram-negative 
bacterium. Deletion of csaA, pamABCDE, or both csaA and pamABCDE resulted in no 
growth defects on solid agar and had no effect on survival in the presence of 50% HI-NHS. 
KK01 and the mutant derivatives maintained stable bacterial counts over the course of the 
1 hr assay in HI-NHS (data not shown). Survival in NHS by the capsule mutant (strain 
KK01csaA) or the exopolysaccharide mutant (strain KK01pam) was not affected and was 
similar to the survival of wild-type strain KK01 (Fig. 5B). In contrast, survival in NHS by 
the double mutant lacking both capsule and exopolysaccharide (strain KK01csaApam) was 
markedly reduced, with a survival ratio of less than 0.35 (P < 0.05, Fig. 5B). While the 
absence of both capsule and exopolysaccharide resulted in reduced resistance to serum, 
survival of strain KK01csaApam was not reduced to undetectable levels, as observed with 
the serum sensitive controls E. coli DH5a and H. influenzae C54 b-. 
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Figure 5: K. kingae is highly resistant to the bactericidal effects of complement present 
in pooled normal human serum, and elimination of both surface polysaccharides 
decreases serum resistance in K. kingae.  
K. kingae strain KK01 and E. coli strain DH5a (~103 CFU) were incubated with 2%, 
5%, 15%, 25%, or 50% NHS or HI-NHS for 1 h (A). K. kingae strains KK01, 
KK01csaA, KK01pam, and KK01csaApam, E. coli strain DH5a, and H. influenzae (H. 
flu) strains C54+ (encapsulated) and C54- (nonencapsulated) were incubated with 
50% NHS or 50% HI-NHS for 1 h (B). The survival ratio was calculated by dividing 
the NHS CFU counts by the HI-NHS CFU counts. Abbreviations: csaA, KK01csaA; 
pam, KK01pam; csaApam, KK01csaApam. A total of three biological replicates were 
performed (n = 3). Statistical significance was determined with an unpaired Student’s 
t test, and the error bars represent the standard error of the mean. *, P < 0.05.  
 
These results establish that elimination of both capsule and exopolysaccharide is 
critical for increased complement-mediated lysis and demonstrate the potent ability of K. 
kingae to evade complement-mediated lysis. 
2.3.3 Opsonin deposition is increased in the absence of surface 
polysaccharides. 
Elimination of the polysaccharide capsule in other organisms has been shown to 
expose bacterial surface factors and promote antibody recognition and thus activation of 
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complement via the classical pathway (Domenico, Tomas, Merino, Rubires, & Cunha, 
1999; Howard & Glynn, 1971; Tomás, Camprubi, Merino, Davey, & Williams, 1991). To 
determine whether K. kingae-specific antibodies were present in HI-NHS, Western blot 
analyses of whole cell lysates and outer membranes were performed using HI-NHS as the 
primary antibody. Human serum immunoglobulins reacted with proteins present in K. 
kingae whole cell and outer membrane fractions (Fig. 6) To further investigate whether the 
capsule and/or the exopolysaccharide prevents antibody binding, we performed flow 
cytometry assays to determine relative levels of IgG and IgM deposition on the K. kingae 
surface after incubation with HI-NHS as the source of antibodies or with secondary 
antibody alone as a control.  There was negligible fluorescence after the incubation with 
the secondary antibody alone (Fig. 7A and 7B; gray bars), thus demonstrating the absence 
of non-specific binding of the secondary antibody. No significant difference in deposition 
was observed between strain KK01 and the single mutant strains KK01csaA and KK01pam 
after incubation with HI-NHS (Fig. 7A and 7B). In contrast, there was a statistically 
significant increase in deposition of both IgG and IgM on the surface of strain 
KK01csaApam, consistent with our observations regarding serum sensitivity (Fig. 7A and 
7B). 
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Figure 6: Human IgG reactivity to K. kingae whole cell and outer membrane 
fractions. 
 
Whole-cell (WC) and outer membrane (OM) fractions were purified from K. kingae 
strains KK01, KK01csaA, KK01pam, and KK01csaApam. Samples were run on a 
7.5% SDS-PAGE gel, probed with 2% HI-NHS, and followed by an anti-human Ig– 
HRP-conjugated secondary antibody. Molecular sizes in kDa. 
 
 
The constant region of IgG and IgM provides a platform for the initiation of the 
complement cascade (Duncan & Winter, 1988; Gadjeva et al., 2008; Perkins, Nealis, 
Sutton, & Feinstein, 1991; Zlatarova et al., 2006). To determine whether antibody 
deposition activates the classical pathway and leads to activation of the terminal pathway, 
we performed flow cytometry assays to measure the deposition of C4b and C3b, two well-
documented opsonins and products of complement activation, on the bacterial surface. As 
shown in Fig. 7C and 7D, there was no significant difference in binding of C4b and C3b to 
strain KK01 and the single mutant strains KK01csaA and KK01pam. In contrast, there was 
a statistically significant increase in C4b and C3b deposition on strain KK01csaApam, 
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consistent with the increase in antibody deposition and serum sensitivity observed with this 
strain (Fig. 7C and 7D).  
These data suggest that survival of strains KK01, KK01csaA, and KK01pam in 
NHS is due in part to reduced antibody deposition and the resultant absence of activating 
complement fragments on the bacterial surface. Elimination of both the polysaccharide 
capsule and the exopolysaccharide on the bacterial surface results in increased opsonin 
deposition, promoting complement activation.  
 
Figure 7: Opsonin deposition increases in the surface polysaccharide-deficient 
mutant. 
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Binding of IgG (A), IgM (B), C3b (C), or C4b (D) to the bacterial surface was 
determined using flow cytometry. Cells were stained with propidium iodine (PI) prior 
to analysis; 30,000 propidium iodine-positive events per biological replicate were 
analyzed, and a total of three biological replicates were performed (n = 3). The 
percentages represent events that registered as Alexa Fluor 488 positive (AF-488+). 
Black bars, HI-NHS (A and B) or NHS (C and D); gray bars, secondary antibody-
only controls (these bars are negligible in size due to the low signal). Abbreviations: 
csaA, KK01csaA; pam, KK01pam; csaApam, KK01csaApam. Statistical significance 
was determined with an unpaired Student’s t test, and the error bars represent the 
standard error of the mean. *, P < 0.05. 
 
2.3.4 Inhibition of the classical pathway when surface polysaccharides are 
absent restores serum survival and decreases opsonin deposition. 
The deposition of IgG and IgM on the bacterial surface prompts complement 
activation via the classical pathway. Ca2+ is considered necessary to maintain the integrity 
of the C1 complex, which associates with the Fc region of antigen-bound IgG or IgM and 
initiates the complement cascade (Bryant & Jenkins, Jr., 1968; Gadjeva et al., 2008). The 
presence of EGTA in serum resistance assays chelates Ca2+ and thereby inhibits classical 
pathway activation, and the concomitant addition of Mg2+ preserves the alternative 
pathway (Des Prez, Bryan, Hawiger, & Colley, 1975). 
To elucidate the importance of classical pathway activation in serum killing of 
strain KK01csaApam, we performed serum bactericidal assays in the presence of EGTA + 
Mg2+. As expected, survival of strains KK01, KK01csaA, and KK01pam was not 
influenced by the introduction of 9 mM Mg2+ alone, 5 mM EGTA alone, or 9 mM Mg2+ + 
5 mM EGTA (Fig. 8A). Conversely, the survival ratio of strain KK01csaApam in the 
presence of either EGTA alone or EGTA + Mg2+ were restored to levels similar to the 
survival ratio of strains KK01, KK01csaA, and KK01pam (Fig. 8A). As anticipated, the 
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presence of Mg2+ alone had no effect on the survival ratio of strain KK01csaApam (Fig. 
8A).  
 
Figure 8: Inhibition of the classical pathway restores survival and reduces C3b 
deposition in the surface polysaccharide-deficient mutant.  
 
Serum survival was assessed with either 50% NHS alone, 50% NHS plus 9 mM Mg2+, 
50% NHS plus 5 mM EGTA, 50% NHS plus 9 mM Mg2+ and 5 mM EGTA, or 50% 
HI-NHS for 1 h (A). The survival ratio was calculated by dividing the NHS CFU 
counts by the HI-NHS CFU counts. K. kingae strains were fixed and incubated for 15 
min in medium alone, in medium containing 20% NHS, or in medium containing 20% 
NHS plus 9 mM Mg2+ and 5 mM EGTA (B). Binding of C3b (n = 3) to the bacterial 
surface was determined using flow cytometry, and 30,000 propidium iodine-positive 
events per experiment were analyzed. The percentages represent events that 
registered as Alexa Fluor 488 positive. Black bars, NHS; white bars, NHS plus 9 mM 
Mg2+ and 5 mM EGTA; gray bars, secondary antibody-only control. Abbreviations: 
csaA, KK01csaA; pam, KK01 pam; csaApam, KK01 csaApam. Statistical significance 
was determined with an unpaired Student’s t test, and the error bars represent the 
standard error of the mean. n.s., not significant; *, P < 0.05.  
 
In order to confirm that chemical inhibition of the classical pathway via EGTA 
prevents complement activation, flow cytometry assays were performed to determine the 
percentage of C3b deposition on the surface of K. kingae in the presence of EGTA + Mg2+. 
As shown in Fig. 8B, no significant differences in C3b deposition were observed between 
strains KK01, KK01csaA, and KK01pam in the presence or absence of EGTA + Mg2+. In 
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contrast, there was a significant decrease in C3b deposition on strain KK01csaApam when 
this strain was incubated in NHS containing EGTA + Mg2+ (Fig. 8B). C3b deposition on 
strain KK01csaApam in NHS containing EGTA + Mg2+ mirrored the C3b deposition on 
strain KK01csaApam in media alone (Fig. 8B). Taken together, these data provide further 
support that the classical complement pathway is activated in the absence of K. kingae 
surface polysaccharides. 
2.3.5 The four distinct capsule types of K. kingae promote serum survival 
in isogenic strains. 
To date, a total of four distinct capsule types have been identified in diverse 
collections of K. kingae clinical isolates, including type a ([3)-β-GalpNAc-(1à5)-β-Kdop-
(2à]), type b ([6)-α-D-GlcpNAc-(1à5)-β-(8-OAc)Kdop-(2à]), type c ([3)-β-D-Ribf-
(1à2)-β-D-Ribf-(1à2)-β-D-Ribf-(1à4)-β-Kdop-(2à]), and type d ([P-(Oà3)[β-D-
Galp-(1à4)]-β-D-GlcpNAc-(1à3)-α-D-GlcpNAc-1-]) (Porsch et al., 2017; Starr et al., 
2013; Starr, Porsch, Seed, Heiss, et al., 2016; Starr, Porsch, Seed, & St. Geme III, 2016). 
The prototype strain KK01 used in this study expresses the type a capsule. To assess 
whether the four capsule types have different abilities to protect the organism against 
complement-mediated lysis, we performed bactericidal assays on isogenic derivatives of 
strain KK01pam expressing either capsule type a (strain KK01Swapcsa), capsule type b 
(strain KK01Swapcsb), capsule type c (strain KK01Swapcsc), or capsule type d (strain 
KK01Swapcsd) (Starr, Porsch, Seed, Heiss, et al., 2016). As shown in Fig. 9A, all four 
capsule types were associated with a survival ratio of 0.80, similar to the survival ratio of 
strain KK01. These data suggest that the presence of any of the four K. kingae capsule 
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types is protective and is adequate for promoting serum resistance in the absence of 
exopolysaccharide in vitro. 
 
Figure 9: Specific capsule types do not dictate serum sensitivity in K. kingae clinical 
isolates. 
 K. kingae strains (~103 CFU) were incubated with either 50% NHS or 50% HI-NHS 
for 1 h. The survival ratio was calculated by dividing the CFU counts in NHS by the 
CFU counts in HI-NHS for isogenic derivatives of strain KK01pam (A) or clinical 
isolates of K. kingae (B). Abbreviations: Empty, nonencapsulated strain 
KK01SwapEmptypam; csa, capsule type a KK01Swapcsapam; csb, type b 
KK01Swapcsbpam; csc, type c KK01Swapcscpam; csd, type d KK01Swapcsdpam; 98, 
K. kingae clinical isolate PYKK98; 93, K. kingae clinical isolate PYKK93; 58, K. 
kingae clinical isolate PYKK58; 46, K. kingae clinical isolate KK146; 60, K. kingae 
clinical isolate PYKK60; 30, K. kingae clinical isolate ATCC 23330; 39, K. kingae 
clinical isolate E3339; 70, K. kingae clinical isolate BB270. A total of three biological 
replicates were performed (n = 3). Statistical significance was determined with an 
unpaired Student’s t test, and the error bars represent the standard error of the mean. 
*, P < 0.05.  
2.3.6 K. kingae clinical isolates show moderate to high levels of serum 
resistance. 
Serum resistance plays an important role in pathogenicity and has been shown to 
be variable from strain to strain in other bacterial species. To determine the variability of 
serum resistance across K. kingae clinical isolates, we performed serum bactericidal assays 
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on eight clinical isolates that represented all four capsular groups and included both 
invasive and healthy carrier isolates (Fig. 9B, Table 2). Additionally, the eight clinical 
isolates contain the pam locus and produce exopolysaccharide. K. kingae strains PYKK98, 
KK146, ATCC23330, and BB270 showed high levels of serum resistance, with a survival 
ratio of approximately 0.80 (Fig. 9B), while strains PYKK93, PYKK58, PYKK60, and 
E3339 showed moderate levels of serum resistance, with survival ratios between 0.40 and 
0.60 (Fig. 9B). The results demonstrate that the clinical isolates tested were resistant to 
human serum; however, there was no consistent distinction in level of susceptibility in 
relation to capsule type or clinical site of isolation.  
2.3.7 Capsule and exopolysaccharide are required for full K. kingae 
virulence in a juvenile rat infection model. 
Given the importance of the capsular polysaccharide and exopolysaccharide in 
protecting K. kingae from the bactericidal effects of human serum in vitro, we sought to 
elucidate the role of these factors in vivo. To examine the role of the K. kingae surface 
polysaccharides in virulence and to determine the influence of complement in limiting 
infection in vivo, we modified a previously described juvenile rat infection protocol (Starr, 
Porsch, Seed, & St. Geme III, 2016). Briefly, we injected 5-day-old Sprague-Dawley rat 
pups via the intraperitoneal (i.p.) route with either phosphate-buffered saline (PBS) alone 
or PBS with 10 ng of cobra venom factor (CVF), which forms a complex with complement 
components factor B and factor D and creates a convertase that depletes C3 and C5 to 
undetectable levels in the serum (Bauman, 1978; Van den Berg, Aerts, & Van Dijk, 1991). 
CVF has been used previously in different animal models, including juvenile rats, to 
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successfully deplete complement in vivo (Kauppi-Korkeila, van Alphen, Madore, Saarinen, 
& Käyhty, 1996; Till, Morganroth, Kunkel, & Ward, 1987; Van den Berg et al., 1991). 
Three hours post injection with PBS alone or PBS with CVF, the rat pups were injected 
i.p. with 1 x 108 cfu of strain KK01, strain KK01csaA, strain KK01pam, or strain 
KK01csaApam, using PBS as a control (Fig. 10A and 10B).  
Among the rat pups that did not receive pretreatment with CVF, all that were 
infected with strain KK01 succumbed to infection, with a median survival of 12 hrs (Fig. 
10A). At five days post-infection, survival among pups infected with strain KK01csaA was 
29% (p < 0.0001, Fig. 10A), and survival among pups infected with strain KK01pam was 
53% (p < 0.0001, Fig. 10A). In contrast, all pups injected with strain KK01csaApam were 
alive and healthy at five days post-infection, similar to pups injected with PBS alone (p < 
0.0001, Fig. 10A). These results suggest that elimination of either capsule or 
exopolysaccharide results in reduced virulence of K. kingae and that elimination of both 
capsule and exopolysaccharide results in an avirulent strain.  
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Figure 10: Surface polysaccharides are required for full K. kingae virulence in a rat 
infection model.  
 
Five-day-old Sprague-Dawley rats were injected via the intraperitoneal (i.p.) route 
with either 0.1 ml PBS (A) or 10 µg CVF in 0.1 ml PBS (B). The graphs plot Kaplan-
Meyer survival curves for rats subsequently i.p. injected with 0.1 ml PBS or 1 x 108 
CFU of the KK01 strains in PBS. Data are for 17 (A) and 10 (B) animals infected with 
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each strain and 15 (A) and 9 (B) animals injected with PBS. Abbreviations: csaA, 
KK01csaA; pam, KK01pam; csaApam, KK01csaApam. 
  
 
Among pups that received CVF pretreatment, all infected with strain KK01, strain 
KK01csaA, strain KK01pam, or strain KK01csaApam succumbed to infection within 12 
hrs (Fig. 10B). All pups injected with PBS alone after CVF pretreatment survived five days 
post-infection (Fig. 10B). These results suggest that resistance to complement via the 
polysaccharide capsule and the exopolysaccharide is critical for K. kingae virulence in 
juvenile rats. 
2.4 Discussion 
Kingella kingae is a common commensal organism in the oropharynx and is an 
emerging pediatric pathogen that represents a leading etiology of joint and bone infections 
in young children (Chometon et al., 2007a; Yagupsky, 2014; Yagupsky et al., 2011). This 
organism causes disease by breaching the respiratory epithelium, invading the 
bloodstream, and disseminating to distant sites (Amit et al., 2013; Bidet et al., 2013; Kehl-
Fie & St. Geme III, 2007; Yagupsky et al., 2006, 2009). In order to survive in the 
intravascular environment and then disseminate, the organism must evade innate immune 
mechanisms.  
Our initial findings revealed that K. kingae is highly resistant to the bactericidal 
effects of complement present in human serum. Further examination revealed that the 
presence of either the capsule or the exopolysaccharide alone was sufficient to fully prevent 
opsonin deposition and completely protect K. kingae against complement-mediated killing, 
a novel observation. Elimination of both the capsule and the exopolysaccharide was 
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required for efficient binding of opsonins (IgG, IgM, C4b, and C3b) to the bacterial surface 
and for significant complement-mediated killing in vitro. Abrogation of the classical 
complement pathway in vitro restored survival of the capsule/exopolysaccharide double 
mutant, clarifying the mechanism by which these surface polysaccharides promote survival 
in human serum. In agreement with our in vitro data, elimination of both the capsule and 
the exopolysaccharide rendered K. kingae completely avirulent, abolishing morbidity and 
mortality in the juvenile rat infection model. To confirm that the attenuation of strain 
KK01csaApam in vivo was a consequence of efficient activation of complement, pups were 
injected with CVF to eliminate complement. As predicted, the resulting complement 
deficiency was associated with an increase in virulence of all K. kingae strains, including 
strain KK01csaApam.  
In recent years, a number of reports have described bacterial factors associated with 
evasion of complement activity in non-encapsulated organisms (Del Tordello, Vacca, Ram, 
Rappuoli, & Serruto, 2014; Griffiths et al., 2011; Hallström, Blom, Zipfel, & Riesbeck, 
2009; Ho, Ram, Nelson, Bonthuis, & Smith, 2007; Murphy, Kirkham, & Lesse, 2006). 
However, bacterial polysaccharide capsules generally predominate as the most potent 
mechanism of bacterial resistance to complement-mediated serum killing, as highlighted 
by studies of H. influenzae, N. meningitidis, and E. coli. In N. meningitidis, transposon 
mutagenesis and large-scale analysis of the genome searching for genes contributing to 
serum resistance identified only genes involved in polysaccharide capsule or 
lipooligosaccharide synthesis (Geoffroy et al., 2003). Consistent with the conclusion that 
the polysaccharide capsule is important for N. meningitidis serum resistance, almost all 
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meningococcal isolates recovered from blood are encapsulated, while 30-70% of carrier 
isolates are non-encapsulated (Ala’Aldeen et al., 2000; Kugelberg et al., 2008; van Deuren 
et al., 2000). Similarly, in H. influenzae, loss of capsule reduces or eliminates serum 
resistance and overexpression of the serotype b capsule synthesis genes due to duplication 
events promotes greater serum resistance (Noel, Brittingham, Granato, & Mosser, 1996; 
Noel et al., 1992; Swift, Moxon, Zwahlen, & Winkelstein, 1991). In this study, we 
observed that non-encapsulated K. kingae exhibits high levels of serum resistance in vitro, 
similar to the serum resistance of wild-type K. kingae, underscoring the importance of the 
exopolysaccharide.  
In considering our observation that the K. kingae capsule and exopolysaccharide 
play crucial and apparently redundant roles in serving to prevent IgG, IgM, C4b, and C3b 
deposition on the bacterial surface and resultant bacterial lysis, it is noteworthy that the 
capsule is tethered to the bacterial surface via a lipid anchor and the exopolysaccharide is 
unanchored. We presume that the exopolysaccharide is loosely associated with the 
bacterial surface, blocking access of opsonins. In earlier work, we observed that the 
exopolysaccharide can be released from the bacterial surface by resuspending bacteria in 
PBS and vigorously shaking, consistent with a non-covalent mechanism of association 
(Starr et al., 2013). The nature of the association and the balance between surface-
associated and released exopolysaccharide during natural infection are currently unknown.  
Exopolysaccharides in other bacterial species have been studied primarily as major 
contributors to the formation and dispersal of biofilms (Cerning, 1991; De Vuyst & 
Degeest, 1999; Flemming et al., 2007; Nwodo et al., 2012). Exopolysaccharide function 
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depends on the polymer structure and composition and has been studied related to 
adherence, bacterial cell aggregation, water retention, and nutrition (Flemming et al., 2007; 
Flemming & Wingender, 2002; Nwodo et al., 2012). Few studies have characterized 
exopolysaccharides in the context of inhibiting complement deposition and subsequent 
complement and/or leukocyte evasion (Ganguly et al., 2014; Jones & Wozniak, 2017; 
Miajlovic et al., 2014; Mishra et al., 2012). In Pseudomonas aeruginosa, expression of the 
Psl exopolysaccharide serves to protect the organism from neutrophil antimicrobial 
functions; however, Psl does not play a role in evasion of complement-mediated lysis in 
vitro and has been studied only in the context of capsule-deficient organisms, thus 
contrasting with our studies of K. kingae (Mishra et al., 2012). Like K. kingae, 
extraintestinal pathogenic Escherichia coli (ExPEC) produces two surface polysaccharides 
that contribute to serum resistance, namely, a group 2 polysaccharide capsule and an 
exopolysaccharide called colonic acid (Miajlovic et al., 2014). However, while colanic acid 
is important for evasion of complement-mediated killing, the absence of the polysaccharide 
capsule renders ExPEC sensitive to serum even in the presence of colanic acid, suggesting 
that the exopolysaccharide alone is not sufficient for mediating serum resistance and thus 
again contrasting with K. kingae (Miajlovic et al., 2014). In K. kingae, the level of 
protection against complement activation and complement-mediated killing provided by 
the exopolysaccharide mimics the protection provided by the polysaccharide capsule. Thus 
far, two exopolysaccharide structures have been described in K. kingae: à3)-β-Galf-
(1à5)-β-Galf-(1à and à5)-β-Galf-(1à (Bendaoud et al., 2011; Starr et al., 2013). It has 
been reported that biofilm formation and dispersal of K. kingae clinical strain PYKK181 
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is dependent on the PAM galactan exopolysaccharide (Bendaoud et al., 2011). In this study, 
we have shown that the PAM galactan produced by K. kingae strain KK01 prevents 
opsonin deposition and complement activation, providing evidence for a novel function of 
the K. kingae exopolysaccharide.   
In K. kingae, four distinct polysaccharide capsules have been identified, designated 
types a, b, c, and d. Using isogenic derivatives of strain KK01pam, all four capsule types 
were associated with a survival ratio similar to the survival ratio for strain KK01. These 
data suggest that the presence of any naturally occurring K. kingae capsule type is adequate 
to protect KK01pam against serum killing under our in vitro conditions. In addition, eight 
clinical isolates representing all four capsular groups and including both invasive and 
healthy carrier isolates were assessed for serum resistance. Interestingly, these isolates 
exhibited moderate to high levels of serum resistance, with no consistent distinctions in 
level of susceptibility in relation to capsule type or clinical site of isolation. The variability 
in serum survival ratio among the different clinical isolates could be due to strain-to-strain 
variation in the quantity of capsule and/or exopolysaccharide. Despite the contributions of 
capsule and exopolysaccharide to serum resistance, the capsule and exopolysaccharide 
double mutant remained relatively resistant to human serum, with a survival ratio that was 
reduced to ~40% of the level in the parent strain (Fig 5B). This observation highlights the 
presence of additional factors deployed by K. kingae for innate immune evasion and may 
be another explanation for the variability of serum resistance observed in the clinical 
isolates. 
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While our in vitro serum resistance experiments suggest no differences in 
resistance between the wild type strain and the single mutant strains lacking capsule or 
exopolysaccharide, our in vivo studies established that each surface polysaccharide plays a 
role in promoting virulence in juvenile rats. Elimination of either capsule or 
exopolysaccharide resulted in reduced virulence, including a lower mortality rate and 
delayed mortality.  This finding suggests that perhaps capsule and/or exopolysaccharide 
play a role in virulence beyond protecting against humoral immunity in vivo; alternatively, 
serum sensitivity in vitro may be unobservable in the absence of a single surface 
polysaccharide. Along these lines, polysaccharide capsules and exopolysaccharides have 
been implicated in both promoting and dampening host inflammatory responses. The 
zwitterionic capsular polysaccharide A from Bacteriodes fragilis, the gut microfloral 
commensal, is implicated in mediating development of the host immune system through 
induction of CD4+ maturation and by promoting a balanced Th1/Th2 response in mice 
(Surana & Kasper, 2012). Interestingly, Totté et al. have reported that a galactan 
homopolysaccharide in Mycoplasma mycoides subsp. mycoides similar to the K. kingae 
exopolysaccharide binds TLR2 and promotes the production of the anti-inflammatory 
cytokine IL-10 (Totté et al., 2015). Further work is necessary to elucidate the 
immunoregulatory potential of the K. kingae surface polysaccharides both in vitro and in 
vivo. 
In conclusion, both the polysaccharide capsule and the exopolysaccharide of K. 
kingae play a crucial role in preventing opsonin deposition and complement-mediated 
killing, presumably facilitating intravascular survival and resulting in enhanced virulence 
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in vivo. These results highlight an underrecognized function of a bacterial 
exopolysaccharide and provide important information that may facilitate development of a 
polysaccharide-based vaccine against K. kingae. 
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3. Kingella kingae surface polysaccharides promote resistance 
to neutrophil phagocytosis and killing 
3.1 Introduction 
Kingella kingae, a gram-negative coccobacillus, is a common commensal organism 
in the oropharynx of young children (Yagupsky et al., 2009). Despite being an oral 
commensal, K. kingae is a primary cause of osteoarticular infections and a common 
etiology of bacteremia in children between 6 and 36 months of age (Chometon et al., 
2007b; Yagupsky, 2014; Yagupsky et al., 2011). Recent studies have elucidated K. kingae 
surface and secreted factors that promote virulence via adherence to epithelial cells, 
cytotoxicity, and immune evasion (Chang et al., 2014; Kehl-Fie et al., 2008; Kehl-Fie & 
St. Geme III, 2007; Maldonado et al., 2011; Muñoz et al., 2018; Porsch et al., 2012).  
To colonize the oropharynx and survive in the hostile intravascular environment, 
K. kingae must evade innate immunity. K. kingae produces a polysaccharide capsule and a 
galactan homopolymer exopolysaccharide, both of which have been demonstrated to 
contribute to virulence in an infant rat infection model (Muñoz et al., 2018; Starr et al., 
2013; Starr, Porsch, Seed, & St. Geme III, 2016). Recent work has determined that the K. 
kingae polysaccharide capsule and exopolysaccharide confer high-level resistance to 
human serum (Muñoz et al., 2018). Elimination of both surface polysaccharides is 
detrimental to the organism in the presence of human serum, resulting in increased 
deposition of antibodies and complement fragments, and ultimately, complement 
activation and bacterial lysis (Muñoz et al., 2018).  
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Neutrophils are the most abundant leukocyte type in the blood and the predominant 
infiltrating leukocyte type during acute inflammation (D. M. Walker, 2004). These cells 
mobilize to clear pathogenic bacteria through various extracellular and intracellular 
mechanisms and are primed and activated by a variety of inflammatory stimulants, 
including conserved bacterial ligands known as pathogen associated molecular patterns 
(PAMPs). PAMPS are recognized by membrane-associated Toll-like receptors (TLRs), 
and subsequent TLR activation primes neutrophils and promotes phagocytosis, 
degranulation, and production of reactive oxygen species (ROS). 
Given the role of neutrophils in combating microbial invaders, bacteria have 
evolved multiple mechanisms to evade neutrophil-mediating killing. Encapsulation by 
invasive pathogens such as Streptococcus pneumoniae and Neisseria meningitidis has been 
demonstrated to promote bacterial survival by inhibiting neutrophil recognition and 
activation (Beiter et al., 2008; Campos et al., 2004; Hyams et al., 2010). Encapsulation has 
also been demonstrated to prevent antibody recognition of surface antigens present on the 
bacterial surface and to inhibit complement deposition and activation (Geoffroy et al., 
2003; Horwitz & Silverstein, 1980; Hyams et al., 2010; Peterson et al., 1978). Opsonization 
by immunoglobulins and complement components augments neutrophil recognition and 
enhances neutrophil antimicrobial activity, including phagocytosis of opsonized bacteria. 
In this study, we found that the K. kingae polysaccharide capsule promotes 
neutrophil evasion by preventing neutrophil activation, dampening ROS production, and 
inhibiting initial neutrophil binding of K. kingae. Interestingly, we observed a distinctive 
role for the exopolysaccharide in promoting K. kingae survival in the presence of 
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neutrophil antimicrobial peptides and blocking neutrophil phagocytosis of bound bacteria. 
The absence of both the polysaccharide capsule and the exopolysaccharide increased 
neutrophil opsonophagocytosis of K. kingae. This study demonstrates the importance of 
the K. kingae polysaccharide capsule and exopolysaccharide in neutrophil evasion, 
presumably promoting hematogenous dissemination of K. kingae. 
3.2 Methods 
3.2.1 Bacterial strains and growth conditions 
The strains used in this study are listed in Table 3. K. kingae strains were stored at 
-80°C in brain heart infusion (BHI) broth with 20% glycerol. E. coli strains were stored at 
-80°C in Luria-Bertani (LB) broth with 15% glycerol. K. kingae strains were grown at 37°C 
with 5% CO2 on chocolate agar plates supplemented with 50 µg/ml kanamycin or 1 µg/ml 
erythromycin, as appropriate. E. coli strains were grown at 37°C on LB agar or shaking at 
250 rpm in LB broth supplemented with 100 µg/ml ampicillin or 50 µg/ml kanamycin, as 
appropriate.  
 
Table 3: Strains and plasmids used in this study 
Strain Description Reference 
Kingella kingae   
KK01 Nonspreading/noncorroding derivative of 
269-492 
(Kehl-Fie & 
St. Geme III, 
2007) 
KK01 csaA KK01 with csaA deletion (Starr, Porsch, 
Seed, & St. 
Geme III, 
2016) 
KK01 pam KK01 with pamABCDE deletion (Starr et al., 
2013) 
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KK01 csaApam KK01 with csaA deletion and pamABCDE 
deletion 
(Muñoz et al., 
2018) 
KK01 rtx KK01 with rtxACDB deletion  This study 
KK01 csaArtx KK01 with csaA deletion and rtxACDB 
deletion 
This study 
KK01 pamrtx KK01 with pam deletion and rtxACDB 
deletion 
This study 
KK01 csaApamrtx KK01 with csaA deletion, pam deletion, 
and rtxACDB deletion 
This study 
E. coli  
  
DH5a  E. coli F- φ80dlacZ∆M15 ∆(lacZYA-
argF)U169 deoR recA1 endA1 hsdR17(rK
- 
mK
+) phoA supE441 thi-1 gyrA96 relA1  
(Sambrook et 
al., 1989) 
Plasmid Description Reference 
E. coli  
  
pUC19rtxACDB::kan pUC19 with aphA3 kanamycin cassette 
flanked by surrounding 5’ and 3’ regions 
of the rtxACDB locus 
This study 
3.2.2 Strain construction 
Strains KK01 csaA, KK01 pam, and KK01 csaApam were generated as previously 
described (Muñoz et al., 2018; Starr et al., 2013; Starr, Porsch, Seed, & St. Geme III, 2016). 
Briefly, plasmid-based gene disruption constructs were created in E. coli, linearized, and 
introduced into K. kingae using natural transformation. Transformants were recovered by 
selectively plating on chocolate agar plates with the appropriate antibiotic. Gene 
disruptions were confirmed by PCR.  
To generate pUC19rtxBDCA::kan, DNA fragments of the homologous 
recombination targeting sequence corresponding to the ~1 kb upstream of rtxB and the ~1 
kb downstream of rtxA were PCR amplified from strain KK01 genomic DNA using primers 
rtx 5’ For/ rtx 5’ Rev and rtx 3’ For/ rtx 3’ Rev, respectively, and were cloned into pUC19 
(Table 4). A kanamycin resistance cassette was then ligated into the BamHI site located 
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between the cloned upstream and downstream homologous recombination targeting 
sequences. The plasmid was linearized with NdeI and was transformed into strain KK01, 
KK01 csaA, KK01 pam, and KK01 csaApam via natural transformation. Transformants 
were recovered on chocolate agar plates containing 50 µg/ml kanamycin. Correct insertion 
of the gene disruption construct was confirmed via PCR and sequencing of the deletion 
site. 
 
Table 4: Primers used in this study 
Primer Sequence (5’ -3’) Reference 
rtx 5’ For GCAGGAATTCAATCTTGCGAATTTGGTGTG This study 
rtx 5’ Rev GCACGGATCCTCGGGCTGATAAATGCCGAC This study 
rtx 3’ For GCACGGATCCAGCTGAACAACGATTCAATG This study 
rtx 3’ Rev GCAGAAGCTTAGAGCTGCGCGTAACCTATG This study 
 
3.2.3 Neutrophil purification 
Human neutrophils were obtained from healthy adult donors using approved IRB 
protocol IRB 16-012812 at the Children’s Hospital of Philadelphia. Whole blood was 
collected in a Vacutainer K2E 18mg (BD, Franklin Lakes, NJ). Neutrophils were isolated 
as previously described (Ermert, Zychlinsky, & Urban, 2009). Briefly, neutrophils were 
purified using 3% dextran sedimentation for 30 min at room temperature (RT) to separate 
red blood cells (RBCs) from the leukocyte-rich supernatant. The supernatant was 
transferred into a new conical tube, and 1 volume of Hypaque Ficoll (Sigma-Aldrich, St. 
Louis, MO) was added underneath the supernatant. The sample was centrifuged at 300 g 
for 30 min to pellet the neutrophils. The remaining RBCs were subjected to hypotonic lysis 
with cold double-distilled water, and the isotonicity was restored by the addition of RPMI-
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HEPES (RPMI (Lonza, Walkersville, MD) without phenol red, substituted with 10 mM 
HEPES (Sigma-Aldrich, St. Louis, MO)). Neutrophils were pelleted and resuspended in 
RPMI-HEPES for experimental use.  
3.2.4 Neutrophil killing assay 
Killing assays with neutrophils were performed as previously described (Ermert et 
al., 2009). Briefly, neutrophils were diluted to 2.0 x 106 cells/ml, and 500 µl was seeded 
onto 24-well plates in RPMI-HEPES with 1% human serum albumin (HSA) (Alfa Aesar, 
Ward Hill, MA) or 1% normal human serum (NHS) (Immucor, Norcross, GA). Bacteria 
were resuspended to an OD600 of ~0.8 in phosphate-buffered saline (PBS) and added at both 
a high and low multiplicity of infection (MOI), 10:1 or 1:10, respectively, and centrifuged 
at 1000 rpm for 2 min. Samples were incubated for various time points at 37°C with 5% 
CO2. After incubation, the supernatant was removed and placed in 1.5-mL reaction tubes. 
Neutrophils were lysed using cold double-distilled water, wells were scraped, and the 
lysate was added to the corresponding collected supernatants. Serial dilutions of the 
inoculum and reaction samples were plated on chocolate agar plates and incubated 
overnight at 37°C with 5% CO2 to determine CFU counts (limit of detection for plating: 20 
CFU). To perform inhibition assays, neutrophils were incubated with 10 µg/ml 
cytochalasin D (Life Technologies Corp., Frederick, MD), 10 mM N-acetylcysteine 
(MilliporeSigma, Burlington, MA), 4 µM diphenyleneiodonium (XXX), or 1x protease 
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) for 30 min prior to infection with 
bacteria. 
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3.2.5 Oxidative burst studies 
To detect intracellular and extracellular reactive oxidative species (ROS) generated 
by neutrophils, the neutrophils were diluted to 2.0 x 105 cells/ml and seeded onto a white 
tissue culture-treated 96-well microtiter plate with 1% HSA or 1% NHS as previously 
described (Engels, Endert, Kamps, & Van Boven, 1985; Mishra et al., 2012).  The bacteria 
were resuspended to an OD600 of ~0.8 in phosphate-buffered saline (PBS) and added at a 
MOI of 10:1 to wells in the presence of 50 µM luminol. The microtiter plate was 
centrifuged at 100 g for 2 min and the relative amount of ROS generated by neutrophils 
was detected at 5 min intervals over 60 min by luminescence. Phorbol 12-myristate 13-
acetate (PMA) (Alfa Aesar, Wardhill, MA) at a concentration of 40 ng/ml was used as a 
positive control for the generation of ROS by neutrophils. 
3.2.6 Microscopy 
Bacterial ingestion by neutrophils  
To detect binding and phagocytosis of bacteria by neutrophils, neutrophils were 
diluted to 2.0 x 106 cells/ml and seeded onto tissue culture-treated glass coverslips with 1% 
HSA or 1% NHS (Mishra et al., 2012; Tuominen-Gustafsson, Penttinen, Hytönen, & 
Viljanen, 2006). Bacteria were resuspended to an OD600 of ~0.8 in PBS, stained with 5 µg/ml 
CFSE (Tonbo Biosciences, San Diego, CA) for 20 min at 37°C, and washed twice with 
PBS. CFSE-stained bacteria were added at an MOI of 10:1 and centrifuged at 1000 rpm 
for 2 min. Samples were incubated for 30 min at 37°C with 5% CO2. Cells were washed 
twice with PBS to remove non-adherent bacteria and were fixed at RT for 15 min using 
4% paraformaldehyde in PBS. Samples were incubated with anti-K. kingae antibody 
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(1:500) overnight at 4°C. The anti-K. kingae antibody was generated against an acetone 
powder of K. kingae strain KK01 whole bacteria. Cells were washed twice with PBS and 
incubated with a 1:500 dilution of goat anti-guinea pig IgG DyLight 649-conjugated 
antibody (Rockland, Limerick, PA). 
 Visualization of bacteria–neutrophil association was performed by microscopy 
using a Nikon Eclipse Ni-E (Nikon Instruments Inc., Melville, NY) with either a 20x 
objective or 60x oil objective. For quantification, 100 neutrophils per n=1 were chosen at 
random for analysis; the cell-associated versus extracellular bacteria were counted by a 
blinded reader.  
3.2.7 Antibacterial peptide bactericidal assays 
K. kingae strains were grown on chocolate agar plates and then resuspended in PBS. 
Samples were diluted in PBS to obtain a final inoculum of approximately 4.0 x 103 CFU/0.1 
ml. The respective inocula were mixed with polymyxin B (Alfa Aesar, Ward Hill, MA), 
HNP 1-3 (MilliporeSigma, Burlington, MA), or LL-37 (Bachem, Torrance, CA) at various 
concentrations and incubated at 37°C with 5% CO2 for 30 min. After incubation, 9 mM of 
MgCl2 was added to the reaction prior to plating. Serial dilutions of the inoculum and 
reaction samples were plated on chocolate agar plates and incubated overnight at 37°C with 
5% CO2 to determine the CFU counts (limit of detection for plating, 20 CFU).  
3.2.8 Ethics statement 
Blood samples for neutrophil isolation were obtained from healthy adult donors 
that provided oral informed consent under approved Children’s Hospital of Philadelphia 
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Institutional Review Board (CHOP IRB) protocol IRB 16-012812 in compliance with all 
institutional and federal guidelines. Due to the nature of the study, the CHOP IRB indicated 
that oral consent was appropriate and approved its use. Oral informed consent from each 
study participant was recorded on a copy of the Verbal Consent Form, which were 
maintained in the study records. 
3.2.9 Statistical analysis 
Statistical analyses were performed with GraphPad Prism (version 7.0a) software 
for Mac (GraphPad Software, San Diego, CA), where a P value of <0.05 was considered 
statistically significant. The specific statistical tests used for each experiment are specified 
in the figure legends.  
3.3 Results 
3.3.1 The K. kingae capsule and exopolysaccharide prevent neutrophil-
mediated killing of K. kingae. 
In previous work we demonstrated that the polysaccharide capsule and 
exopolysaccharide expressed by K. kingae protect the organism from complement-
mediated lysis and promote virulence in an infant rat model of infection (Muñoz et al., 
2018; Starr et al., 2013; Starr, Porsch, Seed, & St. Geme III, 2016). To further characterize 
the role of these surface polysaccharides in innate immune evasion, we performed 
neutrophil-killing assays using K. kingae strain KK01, the capsule-deficient mutant KK01 
csaA (Starr, Porsch, Seed, & St. Geme III, 2016), the exopolysaccharide-deficient mutant 
KK01 pam (Starr et al., 2013), and the capsule-deficient and exopolysaccharide-deficient 
mutant KK01 csaApam (Muñoz et al., 2018). Using an MOI of 0.1 or 10, the K. kingae 
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strains were incubated with or without purified human neutrophils for 1 hr in the presence 
of 1% normal human serum (NHS) as a source of serum opsonins or 1% human serum 
albumin (HSA) as a control. To assess extracellular and intracellular survival of K. kingae 
in the presence of neutrophils, supernatant and neutrophil lysates were diluted and plated 
to determine colony forming units (CFU). Survival percentage was calculated by dividing 
the recovered CFU by the inoculated CFU.  
 
Figure 11: Elimination of the K. kingae capsule results in K. kingae killing by 
neutrophils.  
 
K. kingae strains KK01 (A), KK01 csaA (B), KK01 pam (C), and KK01 csaApam (D) 
were incubated with human neutrophils at an MOI of 10 or 0.1 for 1 hr in the presence 
of 1% HSA or 1% NHS. Black bars indicate survival in the absence of neutrophils, 
and white bars represent survival in the presence of neutrophils. Survival was 
determined by dividing the recovered CFU by the inoculum CFU. Statistical 
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significance was determined using two-way ANOVA and the Tukey post hoc test. *, P 
< 0.05; **, P < 0.01; ****, P < 0.0001.  
 
Elimination of the capsule, the exopolysaccharide, or both the capsule and the 
exopolysaccharide resulted in no growth defects on solid agar (Muñoz et al., 2018) and had 
no effect on survival in the absence of neutrophils or 1% NHS alone (Fig. 11, black bars 
and Fig. 12). Survival of strains KK01 and KK01 pam was only slightly affected at an MOI 
of 0.1 in the presence of neutrophils with 1% NHS (Fig. 11A, C). Survival of strain KK01 
csaA was reduced in the presence of neutrophils with 1% NHS at both MOIs and in the 
presence of neutrophils with 1% HSA at an MOI of 0.1 with ~60% survival (Fig. 11B). 
Interestingly, survival of strain KK01 csaApam was markedly reduced in the presence of 
neutrophils at both MOIs (Fig. 11D). In contrast to the other strains tested, strain KK01 
csaApam was more susceptible to neutrophil-mediated killing when opsonins were present, 
with ~30% survival with opsonins compared to ~50% survival without opsonins (Fig. 
11D).  These results establish that the capsule is critical for K. kingae neutrophil evasion 
and that the exopolysaccharide plays a conditional protective role when opsonins are 
present and the capsule is absent. 
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Figure 12: Survival of K. kingae in the presence of 1% normal human serum. 
 
K. kingae strains KK01, KK01 csaA, KK01 pam, and KK01 csaApam were incubated 
with 1% normal human serum at an MOI equivalent of 0.1 (white bars) or 10 (black 
bars) for 1 hr in the absence of neutrophils. Survival was determined by dividing the 
recovered CFU by the inoculum CFU. 
3.3.2 The K. kingae capsule inhibits the neutrophil oxidative burst 
response. 
The oxidative burst response generated by human neutrophils is a critical innate 
immune defense mechanism against bacterial pathogens. K. kingae expresses a cytotoxin 
called RtxA that is capable of rapidly killing a variety of human cell types, including 
leukocytes (Chang et al., 2014; Kehl-Fie & St. Geme III, 2007; Maldonado et al., 2011). 
In vitro, strains KK01 and KK01 rtx (a mutant with the rtx locus deleted) demonstrate 
similar survival in the presence of neutrophils at an MOI of 10 (Fig. 13). However, to 
eliminate the influence of the RtxA toxin as a confounding variable on neutrophil activation 
and ROS production in the presence of K. kingae, we deleted the rtx locus in strains KK01, 
KK01 csaA, KK01 pam, and KK01 csaApam. To determine the oxidative burst response, 
we incubated the K. kingae rtx mutant strains at an MOI of 10 with human neutrophils and 
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either 1% HSA or 1% NHS in the presence of luminol (Fig. 14A-C). Based on 
measurement of chemiluminescence (relative light units, RLU) at 5 min intervals over a 1 
hr incubation period, incubation of strains KK01 rtx and KK01 pamrtx with neutrophils 
resulted in a moderate neutrophil response when compared to the uninfected control (Fig. 
14A, B). In contrast, incubation of strains KK01 csaArtx and KK01 csaApamrtx resulted 
in a rapid and robust neutrophil response, peaking at the 25 min time point (Fig. 14A, B).  
 
Figure 13: Elimination of RtxA toxin has no effect on K. kingae survival in the 
presence of neutrophils. 
 
K. kingae strains KK01 (A), KK01 rtx (A), KK01 csaA (B), KK01 csaArtx (B), KK01 
pam (C), KK01 pamrtx (C), KK01 csaApam (D), and KK01 csaApamrtx (D) were 
incubated with human neutrophils at an MOI of 10 for 1 hr in the presence of 1% 
HSA (white bars) or 1% NHS (black bars). Survival was determined by dividing the 
recovered CFU by the inoculum CFU. 
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Focusing on the 25 min time point, the neutrophil response was compared across 
the KK01 rtx mutant strains in either 1% HSA or 1% NHS. In both 1% HSA and 1% NHS, 
we observed a statistically significant increase in the neutrophil response to strains KK01 
csaArtx and KK01 csaApamrtx when compared to strain KK01 rtx (Fig. 14C). Comparison 
of strains KK01 rtx and KK01 pamrtx in 1% HSA or 1% NHS revealed no statistically 
significant difference in neutrophil response (Fig. 14C). Similarly, comparison of strains 
KK01 csaArtx and KK01 csaApamrtx in 1% HSA revealed no statistically significant 
difference in neutrophil response (Fig. 14C). In contrast, there was a statistically significant 
increase in neutrophil response to strain KK01 csaApamrtx compared to strain KK01 
csaArtx in 1% NHS (Fig. 14C). These data suggest that K. kingae encapsulation prevents 
neutrophil activation and ROS production and release. Moreover, the neutrophil response 
is most robust when both surface polysaccharides are absent and opsonins are present.  
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Figure 14: The absence of the K. kingae capsule results in an enhanced neutrophil 
oxidative burst response.  
 
K. kingae rtx mutant strains were incubated with human neutrophils at an MOI of 10 
in the presence of 1% HSA (A) or 1% NHS (B). Chemiluminescence was measured at 
5-min intervals for 60 min for kinetic analysis (A, B) or at the 25-min time point (C). 
Statistical significance was determined using two-way ANOVA and the Tukey post 
hoc test. RLU, relative light unit; n.s., not significant; **, P < 0.01; ****, P < 0.0001. 
3.3.3 Neutrophil-mediated killing of capsule-deficient K. kingae is 
dependent on phagocytosis and ROS production. 
Neutrophils are recruited early during infection and can eliminate pathogens 
through a variety of mechanisms, including phagocytosis and the oxidative burst (Nathan, 
2006). To determine whether phagocytosis and/or ROS production facilitates killing of 
non-encapsulated K. kingae strains, we performed neutrophil-killing assays in the presence 
of cytochalasin D (Cyto D), the antioxidant N-acetylcysteine (NAC), or the NADPH 
oxidase inhibitor, diphenyleneiodonium (DPI). Using an MOI of 0.1, strains KK01 csaA 
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and KK01 csaApam were incubated with Cyto D, NAC, or DPI pre-treated human 
neutrophils for 30 min. Pretreatment of neutrophils with Cyto D restored survival of strains 
KK01 csaA and KK01 csaApam in the presence of neutrophils (Fig. 15A, B). Pretreatment 
of neutrophils with NAC led to a roughly two-fold increase in the percent survival for 
strains KK01 csaA and KK01 csaApam in 1% HSA and 1% NHS, but did not completely 
restore survival to the level observed with vehicle-only pretreated neutrophils (Fig. 15C, 
D). Similarly, pretreatment of neutrophils with DPI led to a significant increase in the 
percent survival for strain KK01 csaA in 1% HSA (Fig. 15E). Pretreatment of neutrophils 
with DPI led to a roughly two-fold increase in the percent survival for strain KK01 
csaApam but did not completely restore survival (Fig. 15F). These data suggest that 
phagocytosis and ROS are key mechanisms contributing to neutrophil-mediated killing of 
non-encapsulated K. kingae. 
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Figure 15: Inhibition of neutrophil phagocytosis and ROS production enhances 
survival of non-encapsulated K. kingae.  
 
K. kingae strains KK01 csaA and KK01 csaApam were incubated with human 
neutrophils at an MOI of 0.1 for 30 min. Neutrophils were preincubated with 10 µg/ml 
cytochalasin D, Cyto D (A, B), 10 mM N-acetylcysteine, NAC (C, D), or 4 µM 
diphenyleneiodonium (E, F) in the presence of 1% HSA or 1% NHS. Black bars 
indicate survival in the absence of neutrophils, white bars represent survival in the 
presence of neutrophils, and gray bars represent survival in the presence of 
neutrophils pretreated with Cyto D, NAC, or DPI. Survival was determined by 
calculating the recovered CFU by the inoculum CFU. Statistical significance was 
determined using two-way ANOVA and the Tukey post hoc test. n.s., not significant, 
*, P < 0.05; ***, P < 0.001; ****, P < 0.0001. 
 
3.3.4 The K. kingae exopolysaccharide protects against neutrophil 
antimicrobial peptides. 
Neutrophil granules are cytoplasmic vesicles that can fuse with phagosomes or the 
plasma membrane to release degradative enzymes (e.g. myeloperoxidase, elastase, and 
cathepsin G), antimicrobial peptides (e.g. defensins and the cathelicidin LL37), and 
reactive radicals to kill intracellular and extracellular microorganisms (Nathan, 2006). To 
determine whether proteases released during degranulation facilitate killing of K. kingae, 
we performed neutrophil-killing assays in the presence of a protease inhibitor cocktail (PI). 
Using an MOI of 0.1, strains KK01 csaA and KK01 csaApam were incubated with PI-
pretreated human neutrophils for 30 min. Pretreatment of neutrophils with PI had no 
statistically significant effect on levels of survival for strains KK01 csaA and KK01 
csaApam (Fig. 16A, B). To determine the sensitivity of K. kingae in the presence of 
antimicrobial peptides, we performed bactericidal assays with a bacterial peptide, 
polymyxin B, and human peptides, LL-37 and HNP 1-3, at a range of physiologic 
concentrations. Survival of strain KK01 csaA compared to strain KK01 was not affected 
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in the presence of polymyxin B and was slightly decreased in the presence of LL-37 (Fig. 
16C, D). Interestingly, survival of strain KK01 pam compared to strain KK01 was 
significantly decreased in the presence of polymyxin B or LL-37 (Fig. 16C, D). Strain 
KK01 csaApam was most sensitive in the presence of polymyxin B and LL-37 compared 
to strain KK01 (Fig. 16C, D). We observed no change in survival of the mutant strains 
compared to strain KK01 in the presence of HNP 1-3 (Fig. 16E). These results establish 
that the exopolysaccharide is critical for survival of K. kingae in the presence of 
antimicrobial peptides and demonstrate a moderate role for the capsule. 
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Figure 16: The surface polysaccharides protect K. kingae against antimicrobial 
peptides.  
 
K. kingae strains KK01 csaA and KK01 csaApam were incubated with human 
neutrophils preincubated with a protease inhibitor cocktail (PI) at an MOI of 0.1 for 
30 min in the presence of 1% HSA or 1% NHS (A, B). Black bars indicate survival in 
the absence of neutrophils, white bars represent survival in the presence of 
neutrophils, and gray bars represent survival in the presence of neutrophils 
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pretreated with PI. K. kingae strains and E. coli strain DH5a were incubated with 
various concentrations of antimicrobial peptides, polymyxin B (C), cathelicidin LL-
37 (D), or HNP1-3 (E) for 30 min. Survival was determined by calculating the 
recovered CFU by the inoculum CFU. 
 
3.3.5 The K. kingae surface polysaccharides inhibit neutrophil binding 
and phagocytosis of bacteria. 
To further delineate the mechanism of neutrophil-mediated killing of K. kingae 
strains, we performed immunofluorescence microscopy, examining the number of K. 
kingae associated with neutrophils and the nature of association. K. kingae rtx mutant 
strains were used to prevent cell lifting during infection. K. kingae strains were stained 
with carboxyfluorescein succinimidyl ester (CFSE) prior to infection and were incubated 
at an MOI of 10 with human neutrophils for 30 min or 60 min in presence of 1% HSA or 
1% NHS. The wells were washed vigorously to remove any unassociated bacteria, and the 
samples were incubated with an anti-K. kingae whole organism guinea pig antiserum to 
detect extracellular bacteria associated with the neutrophils. For the 30 min time point, the 
total number of associated bacteria (intracellular and extracellular) was 2.8-fold higher for 
strain KK01 csaArtx compared to strain KK01 rtx in 1% HSA and 1.6-fold higher for strain 
KK01 csaArtx compared to strain KK01 rtx in 1% NHS (Fig. 17A, Table 5). The total 
number of associated bacteria was 4.0-fold higher for strain KK01 csaApamrtx compared 
to strain KK01 rtx in 1% HSA and 3.1-fold higher for strain KK01 csaApamrtx compared 
to strain KK01 rtx in 1% NHS (Fig. 17A, Table 5). While we observed an increase in total 
bacterial association with strain KK01 csaArtx compared to strain KK01 rtx, there was no 
significant difference between the number of intracellular bacteria (Fig. 17B, C, Table 5). 
In contrast, we observed a significant increase in the number of intracellular KK01 
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csaApamrtx compared to strains KK01 rtx, KK01 csaArtx, and KK01 pamrtx in 1% HSA 
and 1% NHS (Fig. 17B-E). We also observed a statistically significant increase in the total 
number of associated bacteria for strain KK01 csaApamrtx in 1% NHS compared to 1% 
HSA (Table 5).  
At the 60 min time point, we observed an increase in total number of associated 
bacteria for strains KK01 rtx, KK01 csaArtx, and KK01 pamrtx; however, the number of 
intracellular bacteria remained similar across the 30 min and 60 min time points (Table 5, 
Fig. 17B-D, F-H). We observed a slight increase in total number of associated bacteria for 
strain KK01 csaApamrtx at 60 min (Table 5). Comparing the 60 min time point to the 30 
min time point, there was a significant decrease in the number of extracellular bacteria and 
a slight increase in the number of intracellular bacteria for strain KK01 csaApamrtx (Fig. 
17E, I).  
Taken together, these results demonstrate that the absence of capsule results in 
increased bacterial association with neutrophils and that only the elimination of both the 
capsule and the exopolysaccharide results in a significant increase of K. kingae 
phagocytosis by neutrophils, regardless of opsonin deposition. 
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Figure 17: The presence of the K. kingae surface polysaccharides results in reduced 
neutrophil association and phagocytosis of K. kingae.  
 
Immunofluorescence images (A) and quantitative analysis (B-I) of K. kingae rtx 
mutant strains incubated with human neutrophils at an MOI of 10 for 30 min (A-I) 
or 60 min (B-I) in the presence of 1% HSA or 1% NHS.  K. kingae strains were stained 
with CFSE (green) prior to infection. Neutrophils were fixed and incubated with a 
guinea pig anti-K. kingae antiserum and subsequently with anti-guinea pig AF-649 to 
detect extracellular bacteria (red).  DAPI was used to stain the nuclei of the 
neutrophils (blue). Images were acquired using a 20x objective. Arrows indicate 
extracellular bacteria, and arrowheads indicate intracellular bacteria. Scale bar is 
equal to 5 µm. Graphs depict the total number of CFSE+/AF649- (intracellular, B-E) 
events and the total number of CFSE+/AF649+ (extracellular, F-I) for strains KK01 
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rtx (B, F), KK01 csaArtx (C, G), KK01 pamrtx (D, H), and KK01 csaApamrtx (E, I). 
The data represents total number of CFSE+ events per 100 neutrophils chosen 
randomly per n=1. Abbreviations: H, HSA; N, NHS; KK, K. kingae; ecKK, 
extracellular K. kingae.   
 
Table 5: Total number of CFSE- bacteria associated with human neutrophils 
 
*The number (mean ± SD) of associated bacteria is indicated in parentheses. The data 
represents total number of CFSE+ events per 100 neutrophils chosen randomly per 
n=1. 
 
3.4 Discussion 
 
The pathogenesis of K. kingae disease involves bacterial invasion of the 
bloodstream, evasion of complement- and neutrophil-mediated killing, and dissemination 
to distant sites (Amit et al., 2013; Bidet et al., 2013; Kehl-Fie & St. Geme III, 2007; 
Yagupsky et al., 2006, 2009). The K. kingae surface polysaccharides have proven to be 
critical for complement evasion, and expression of both the capsule and the 
exopolysaccharide is essential for full virulence in the infant rat model of infection (Muñoz 
et al., 2018). In this study, we observed that in the absence of the polysaccharide capsule, 
K. kingae was sensitive to neutrophil-mediated killing. This phenotype was enhanced when 
Strain 1% HSA 1% NHS 
 30 min 
 
60 min 30 min 60 min 
KK01 rtx (21±8.2) (59±9.2) 
 
(35±7.0) 
 
(43±13.1) 
 
KK01 csaArtx (59 ± 9.5) 
 
(79±7.1) 
 
(56 ±3.6) 
 
(79±2.3) 
 
KK01 pamrtx (36 ± 5.5) 
 
(58±5.9) 
 
(38 ± 3.2) 
 
(45±11.7) 
 
KK01 
csaApamrtx 
(85 ± 9.0) 
 
(96±9.0) 
 
(109 ± 7.8) 
 
(95±9.5) 
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the exopolysaccharide was also absent. Further analysis demonstrated that the 
polysaccharide capsule prevented neutrophil ROS production and interfered with 
neutrophil binding of K. kingae but had a limited effect on resistance to neutrophil 
antimicrobial peptides and no direct effect on phagocytosis. In contrast, the 
exopolysaccharide conferred resistance to neutrophil antimicrobial peptides and blocked 
neutrophil phagocytosis but had a limited effect on neutrophil binding of K. kingae. 
Overall, we have established a novel interplay between the K. kingae polysaccharide 
capsule and exopolysaccharide, which have complementary but distinct roles in mediating 
resistance to human neutrophils. 
Polysaccharide capsules expressed by invasive pathogens such as N. meningitidis 
and S. pneumoniae promote bacterial survival during infection by interfering with 
neutrophil recognition, activation, and phagocytosis (Hyams et al., 2010; Spinosa et al., 
2007; Wartha et al., 2007). In this study, we demonstrated that the presence of the K. kingae 
polysaccharide capsule significantly reduced the oxidative burst response by neutrophils. 
Many encapsulated pathogens prevent ROS production by inhibiting serum opsonization 
(Horwitz & Silverstein, 1980; Hyams et al., 2010; Peterson et al., 1978). In the case of K. 
kingae, elimination of the polysaccharide capsule increased ROS production regardless of 
the presence of human serum. Interestingly, only elimination of both the polysaccharide 
capsule and the exopolysaccharide led to a significant increase in ROS production when 
opsonins were present. These data are consistent with our previous study demonstrating 
that the presence of either the polysaccharide capsule or the exopolysaccharide was 
sufficient to prevent opsonization of K. kingae (Muñoz et al., 2018). Our results suggest 
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that encapsulation prevents ROS production through mechanisms beyond hindering 
opsonin deposition. We hypothesize that when the K. kingae polysaccharide capsule is 
absent, increased neutrophil recognition of bacterial lipopolysaccharide (LPS) prompts 
TLR4 activation. TLR4 is activated by LPS and upon activation recruits the NADPH-
oxidase complex, Nox4, leading to the generation of ROS (Kaisho & Akira, 2006; Ngkelo, 
Meja, Yeadon, Adcock, & Kirkham, 2012; Park et al., 2004; Qureshi et al., 1999). Future 
studies will assess the stimulatory potential of K. kingae LPS.  
Aside from preventing ROS production, the K. kingae polysaccharide capsule 
decreased the total number of neutrophil-associated bacteria. It is well-documented that 
bacterial polysaccharide capsules prevent neutrophil association by blocking opsonization 
(Horwitz & Silverstein, 1980; Hyams et al., 2010; Peterson et al., 1978). Interestingly, in 
our studies neutrophil binding of K. kingae occurred regardless of opsonization, similar to 
ROS production. Studies have shown nonopsonic neutrophil interactions by N. 
gonorrhoeae and H. pylori through the expression of adhesins on the bacterial surface 
(Craig, Lackie, Parton, & Freer, 1988; Fischer & Rest, 1988; Rautelin, Blomberg, Jårnerot, 
& Danielsson, 1994; Rest & Frangipane, 1992). In our previous work, we established that 
the K. kingae polysaccharide capsule can interfere with adherence to epithelial cells 
(Porsch et al., 2012). In the absence of type IV pili, the polysaccharide capsule masks the 
trimeric autotransporter, Knh, and deletion of the capsule locus restores Knh-mediated 
adherence to wild-type levels (Porsch et al., 2012). Neutrophil-killing assays have not been 
performed using Knh-deficient or pili-deficient K. kingae strains to determine whether 
association with neutrophils is affected by these adhesins.  
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It is noteworthy that despite an increase in the total number of bound bacteria, the 
elimination of capsule did not increase phagocytosis regardless of opsonization. This 
observation suggests that the K. kingae exopolysaccharide inhibits or delays neutrophil 
phagocytosis. Exopolysaccharide secretion in other bacterial pathogens is commonly 
associated with biofilm formation, promoting survival in the host by inhibiting 
opsonization and phagocytosis (Jesaitis et al., 2003; Jones & Wozniak, 2017; Yamanaka 
et al., 2011). Based on previous studies, we presume that the K. kingae exopolysaccharide 
remains loosely tethered to the K. kingae cell surface, at least in part (Muñoz et al., 2018; 
Starr et al., 2013). Surface analysis using scanning electron microscopy may be beneficial 
for identifying structural or physical changes in the K. kingae cell surface that alter 
interactions with human neutrophils to inhibit or reduce neutrophil phagocytosis. 
Alternatively, the presence of the exopolysaccharide on the K. kingae bacterial surface may 
mask surface antigens that are recognized by neutrophil receptors and trigger phagocytosis.  
Cationic antimicrobial peptides function through electrostatic interactions with 
anionic bacterial surfaces (Brogden, 2005; Hancock & Chapple, 1999; Nicolas & Mor, 
1995; Martti Vaara, 1992). While bacterial polysaccharide capsules vary in their polymer 
composition, most capsules are anionic and have been shown to bind antimicrobial peptides 
to prevent or reduce undesirable interactions with the bacterial surface (Campos et al., 
2004; Spinosa et al., 2007; Wartha et al., 2007). Surprisingly, there are cases where the 
lack or loss of the polysaccharide capsule increases resistance to antimicrobial peptides, 
with examples including S. pneumoniae and Campylobacter jejuni (Beiter et al., 2008; 
Zilbauer et al., 2005). Given that the K. kingae polysaccharide capsule blocks antibody 
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recognition of surface antigens (Muñoz et al., 2018), we hypothesized that the capsule 
would be necessary for complete protection against antimicrobial peptides. Interestingly, 
loss of the polysaccharide capsule had no effect on K. kingae survival in the presence of 
polymyxin B and only slightly affected survival in the presence of cathelicidin LL-37. In 
contrast, elimination of the exopolysaccharide resulted in a marked decrease in K. kingae 
survival in the presence of increasing concentrations of either polymyxin B or LL-37 when 
compared to the wild-type strain, suggesting that the exopolysaccharide is essential for 
antimicrobial peptide resistance. Llobet et al. demonstrated that free capsular material shed 
or purified from K. pneumoniae, S. pneumoniae, or Pseudomonas aeruginosa acted as a 
decoy by sequestering and neutralizing polymyxin B and HNP-1 (Llobet, Tomás, & 
Bengoechea, 2008). The secretion and release of the high molecular weight 
exopolysaccharide by K. kingae may provide a physical barrier and also actively scavenge 
antimicrobial peptides to protect K. kingae more efficiently than the polysaccharide 
capsule. Similar to K. kingae survival in the presence of neutrophils, elimination of both 
the capsule and the exopolysaccharide led to the most sensitive phenotype in assays with 
antimicrobial peptides, suggesting that the capsule plays a minor role in protection when 
the exopolysaccharide is absent. 
Given the robust oxidative burst response and phagocytic activities of neutrophils 
in assays with surface polysaccharide-deficient K. kingae, pretreatment of neutrophils with 
ROS inhibitors, DPI and NAC, or an actin polymerase inhibitor, Cyto D, restored survival 
of K. kingae mutants to wild-type levels. Together, our data suggest that killing of the 
capsule-deficient K. kingae strains is predominately due to ROS production, whereas the 
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enhanced killing of the capsule-deficient and exopolysaccharide-deficient K. kingae is 
meditated through both ROS production and phagocytosis. Furthermore, degranulation and 
release of antimicrobial peptides by neutrophils may augment killing of 
exopolysaccharide-deficient K. kingae. 
In our earlier work, we observed redundancy of the the K. kingae polysaccharide 
capsule and exopolysaccharide in preventing antibody and complement deposition on the 
bacterial surface (Muñoz et al., 2018). In this study, we observed largely distinct but 
interdependent roles for the polysaccharide capsule and the exopolysaccharide in 
protecting K. kingae from neutrophil-mediated killing and antimicrobial peptides. This 
study demonstrates the protective functions of the K. kingae polysaccharide capsule and 
exopolysaccharide against human neutrophils and highlights the robust and multifaceted 
mechanisms employed by K. kingae to evade innate immunity. 
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4. Diversity and genetic characterization of the Kingella kingae 
exopolysaccharide among clinical isolates 
4.1 Introduction 
Kingella kingae is a fastidious gram-negative oropharyngeal commensal bacterium 
in humans and has been described as an emerging pediatric pathogen (Yagupsky et al., 
2009, 2011). In previous work, we described the production of two surface 
polysaccharides, the polysaccharide capsule and the exopolysaccharide, by the K. kingae 
strain KK01 (a septic arthritis clinical isolate). Genetic and structural analyses of the 
capsule synthesis loci from a diverse collection of K. kingae clinical isolates established 
the presence of four distinct capsule types (types a, b, c, and d) (Starr, Porsch, Seed, Heiss, 
et al., 2016).  Interestingly, capsule types a and b were predominant among invasive disease 
isolates suggesting an association between capsule type and clinical presentation (Porsch 
et al., 2017; Starr, Porsch, Seed, Heiss, et al., 2016). While the genetic determinants and 
diversity of the K. kingae polysaccharide capsule have been extensively studied, little is 
known about the exopolysaccharide synthesis locus, pamABCDE, and diversity among 
carrier and invasive clinical isolates. 
Exopolysaccharide function depends on the polymer structure and composition and 
in other bacterial species has been studied primarily as a major contributor to the formation 
and dispersal of biofilms (Cerning, 1991; De Vuyst & Degeest, 1999; Flemming et al., 
2007; Nwodo et al., 2012). Thus far, two galactan homopolymer exopolysaccharide 
structures with distinct linkages have been described in K. kingae: à5)-β-Galf-(1à and 
à3)-β-Galf-(1à5)-β-Galf-(1à (Bendaoud et al., 2011; Starr et al., 2013), which we refer 
to as the type 1 and type 2 exopolysaccharide, respectively. Based on previous studies of 
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K. kingae strain KK01, the type 1 exopolysaccharide by prevents opsonin deposition and 
complement activation, protecting the organism from human serum (Muñoz et al., 2018). 
In studies of K. kingae strain PYKK181, the type 2 exopolysaccharide has been 
demonstrated to contribute to biofilm dispersal (Bendaoud et al., 2011). The ability of the 
K. kingae exopolysaccharides to inhibit biofilm formation and promote serum resistance 
may benefit K. kingae during colonization and invasive disease. Further analysis of the 
biosynthesis genes and/or machinery will provide a better foundation to determine the 
presence and diversity of exopolysaccharides in K. kingae clinical isolates. Interestingly, 
the exopolysaccharide pam loci present in strains KK01 and PYKK181 are highly 
homologous.  
In this study, we describe the genetic composition of the pam locus and found two 
distinct alleles that correlate with the exopolysaccharide types. Furthermore, using PCR-
typing, we examine the diversity of the exopolysaccharide among carrier and invasive 
clinical isolates and established that over 99% of all isolates express the type 1 
exopolysaccharide. Both the type 1 and type 2 exopolysaccharides promote serum 
resistance in K. kingae isolates. Notably, the lack of diversity of the exopolysaccharide 
among isolates makes the exopolysaccharide a preferential target for polysaccharide-
conjugate vaccines.  
4.2 Methods 
4.2.1 Bacterial strains and growth conditions 
The strains used in this study are listed in Table 6. K. kingae strains were stored at 
-80°C in brain heart infusion (BHI) broth with 20% glycerol. E. coli strains were stored at 
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-80°C in Luria-Bertani (LB) broth with 15% glycerol. K. kingae strains were grown at 37°C 
with 5% CO2 on chocolate agar plates supplemented with 50 µg/ml kanamycin or 1 µg/ml 
erythromycin, as appropriate. E. coli strains were grown at 37°C on LB agar or shaking at 
250 rpm in LB broth supplemented with 100 µg/ml ampicillin or 50 µg/ml kanamycin, as 
appropriate.  
4.2.2 Strain construction 
Gene disruptions were introduced into K. kingae by natural transformation (Kehl-
Fie et al., 2008). Following recovery, transformants were plated on selective medium and 
correct insertion of the gene disruption construct was confirmed via PCR and sequencing 
of the insertion site. All of the plasmids used in this study are listed in Table 6, and the 
sequences of all of the primers used are listed in Table 7.  
The strains KK01 csaA, KK01 pam, and KK01csaApam were generated as 
previously described (Muñoz et al., 2018; Starr et al., 2013; Starr, Porsch, Seed, & St. 
Geme III, 2016). To generate mutants with deletion of pamABC or pamDE, strains KK01 
and KK01csaA were transformed with the linearized disruption plasmids 
pUC19pamABC::kan or pUC19pamDE::kan. To generate pUC19pamABC::kan, DNA 
fragments of the homologous recombination targeting sequence corresponding to ~1 kb 
upstream of pamA and ~1 kb downstream of pamC were PCR amplified from strain KK01 
genomic DNA using primers pam 5’ For/ pamABC 5’ Rev and pamABC 3’ For/ pamABC 
3’ Rev, respectively, and were ligated into pUC19. To generate pUC19pamDE::kan, DNA 
fragments of the homologous recombination targeting sequence corresponding to ~1 kb 
upstream of pamD and ~1 kb downstream of pamE were PCR amplified from strain KK01 
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genomic DNA using primers pamDE 5’ For/ pamDE 5’ Rev and pam 3’ For/ pam 3’ Rev, 
respectively, and were ligated into pUC19. For both plasmids, a kanamycin resistance 
cassette was then ligated into the BamHI site located between the cloned upstream and 
downstream homologous recombination targeting sequences.  
To generate strain KK143csb, strain KK143 was transformed with the linearized 
disruption plasmid pSwapEmpty (Starr, Porsch, Seed, Heiss, et al., 2016). To generate 
pamABCDE deletion mutants, strains KK143 and KK143csb were transformed with the 
linearized disruption plasmid pUC19pam::ermC (Starr et al., 2013). The plasmids were 
purified from E. coli and linearized with NdeI. 
To generate pUC19pamABC, DNA fragments were amplified from strain KK01 
genomic DNA by PCR using primers pam Amp For/ pamABC Amp Rev and were ligated 
into pUC19. Plasmids pUC19EmptyVector and pUC19pamABC were transformed into E. 
coli strain DH5a by electroporation, and transformants were recovered by plating on agar 
supplemented with 100 µg/ml ampicillin.  
Table 6: Strains and plasmids used in this study 
Strain Description Reference 
Kingella kingae   
KK01 Nonspreading/noncorroding derivative of 
269-492 
(Kehl-Fie & St. 
Geme III, 2007) 
PYKK181 Clonal group V isolate from patient with 
bacteremia 
Yagupsky, P.  
CC254 Clonal group V isolate from a healthy 
carrier 
Yagupsky, P.  
KK242 Clonal group V isolate from patient with 
bacteremia 
Yagupsky, P.  
KK430 Clonal group V isolate from patient with 
bacteremia 
Yagupsky, P.  
KK143 Clonal group V isolate patient with of 
septic arthritis 
Yagupsky, P.  
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KK405 Clonal group V isolate patient with of 
septic arthritis 
Yagupsky, P. 
Sch1614 Clonal group ϑ isolate from a healthy 
carrier 
Yagupsky, P.  
ATCC23330 Clonal group D isolate from a healthy 
carrier 
ATCC 
KK245 Clonal group A isolate from patient with 
bacteremia 
Yagupsky, P.  
KK247 Clonal group A isolate from patient with 
endocarditis 
Yagupsky, P.  
BB060 Clonal group D isolate from a healthy 
carrier 
Yagupsky, P.  
KK113 Clonal group C isolate from a healthy 
carrier 
Yagupsky, P.  
AA046 Clonal group F isolate from a healthy 
carrier 
Yagupsky, P. 
KK86 Clonal group K isolate from a healthy 
carrier 
Yagupsky, P.  
KK145 Clonal group K isolate from patient with 
septic arthritis 
Yagupsky, P. 
KK12 Clonal group H isolate from a healthy 
carrier 
Yagupsky, P.  
KK136 Clonal group H isolate from patient with 
bacteremia 
Yagupsky, P.  
KK83 Clonal group H isolate from patient with 
septic arthritis 
Yagupsky, P.  
BB012 Clonal group B isolate from a healthy 
carrier 
Yagupsky, P.  
KK142 Clonal group B isolate from patient with 
septic arthritis 
Yagupsky, P.  
KK164 Clonal group P isolate from patient with 
bacteremia 
Yagupsky, P. 
KK144 Clonal group P isolate from patient with 
septic arthritis 
Yagupsky, P.  
KK190 Clonal group P isolate from patient with 
endocarditis 
Yagupsky, P. 
KK141 Clonal group N isolate from patient with 
osteomyelitis 
Yagupsky, P.  
AA068 Clonal group N isolate from a healthy 
carrier 
Yagupsky, P.  
KK245 Clonal group A isolate from patient with 
bacteremia 
Yagupsky, P. 
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EE160 Clonal group A isolate from a healthy 
carrier 
Yagupsky, P.  
BB114 Clonal group A isolate from a healthy 
carrier 
Yagupsky, P. 
KK01csaA Derivative of KK01 with deletion of csaA 
type a capsule synthesis gene 
(Starr, Porsch, 
Seed, & St. 
Geme III, 2016) 
KK01pam Derivative of KK01 with deletion of 
pamABCDE exopolysaccharide locus 
(Starr et al., 
2013) 
KK01csaApam Derivative of KK01 with deletion of csaA 
and pamABCDE locus 
(Muñoz et al., 
2018) 
KK01pamABC Derivative of KK01 with deletion of 
pamABC locus 
This study 
KK01pamDE Derivative of KK01 with deletion of 
pamDE locus 
This study 
KK01csaApamABC Derivative of KK01 with deletion of csaA 
and pamABC locus 
This study 
KK01ScsaApamDE Derivative of KK01 with deletion of csaA 
and pamDE locus 
This study 
KK143csb Derivative of KK143 with deletion of 
csbABC type b capsule synthesis locus 
This study 
KK143pam Derivative of KK143 with deletion of 
pamABCDE exopolysaccharide locus 
This study 
KK143csbpam Derivative of KK143 with deletion of 
csbABC and pamABCDE loci 
This study 
E. coli  
  
DH5a  E. coli F- φ80dlacZ∆M15 ∆(lacZYA-
argF)U169 deoR recA1 endA1 hsdR17(rK
- 
mK
+) phoA supE441 thi-1 gyrA96 relA1  
(Sambrook et al., 
1989) 
Plasmid Description Reference 
E. coli  
  
pUC19pam::ermC pUC19 derivative that contains 
pamABCDE disruption construct marked 
with the ermC erythromycin cassette  
(Starr et al., 
2013) 
pSwapEmpty Contains the capsule synthesis locus 
flanking genes with the capsule synthesis 
variable region deleted 
(Starr, Porsch, 
Seed, Heiss, et 
al., 2016) 
pUC19pamABC::kan pUC19 derivative that contains pamABC 
disruption construct marked with the 
aphA3 kanamycin cassette  
This study 
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pUC19pamDE::kan pUC19 derivative that contains pamDE 
disruption construct marked with the 
aphA3 kanamycin cassette  
This study 
pUC19pamABC pUC19 derivative that contains the 
pamABC locus and upstream promoter  
This study 
 
4.2.3 Polysaccharide extraction and staining 
For capsule extractions, K. kingae strains were grown at 37°C with 5% CO2 on 
chocolate agar plates. Bacteria were resuspended in PBS to an OD600 ~1.2, and cells were 
pelleted, washed, and resuspended in Tris acetate pH 5.0 for 1 hr. Cells were removed by 
centrifugation, and extracts were treated with proteinase K for 1 hr and then concentrated 
as previously described (Porsch et al., 2012). For capsule and exopolysaccharide co-
purifications, bacteria were resuspended in 5 ml PBS and vortexed. Cells were removed by 
centrifugation, and bacterial supernatants were treated with proteinase K for 1 hr and then 
concentrated as previously described (Porsch et al., 2012). 
Aliquots of supernatant and purified capsule from K. kingae derivatives were 
separated on 7.5% and 10% SDS-PAGE gels, respectively. For supernatant samples, SDS-
PAGE gels were treated first with silver staining and subsequently with Alcian blue 
staining. For purified capsule samples, SDS-PAGE gels were treated with 0.125% Alcian 
blue as previously described (Porsch et al., 2012). For silver staining, gels were treated as 
previously described (J. S. Kim et al., 1996).  
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4.2.4 RNA isolation and RT-PCR 
Total RNA from K. kingae strain KK01 was extracted and purified as previously 
described (Kehl-Fie et al., 2009). Briefly, RNA was extracted using TRIreagent (Sigma, 
St. Louis, MO) and the RNeasy minikit by following the lipid-rich tissue protocol (Qiagen, 
Valencia, CA). Residual DNA was removed with RQ1 DNase (Fisher Scientific, 
Pittsburgh, PA). The concentration and purity of the RNA were determined by measuring 
the A260/A280 ratio with a Nanodrop 2000 (Thermo Fisher, Rockford, IL). The qScript 
cDNA SuperMix kit (Quanta Biosciences, Beverly, MA) was used according to the 
manufacturer’s instructions for RT-PCR. The primer sets used for RT-PCR are listed in 
Table 7. 
 
Table 7: Primers used in this study 
Primer Sequence (5’ -3’) Reference 
pam 5’ For GCGAATTCGGCGTTGGTGGAATATCCTG 
 
(Starr, 
Porsch, Seed, 
& St. Geme 
III, 2016) 
pam 3’ For GCGGATCCTCAAAGGCTGGTATAAACAC 
 
(Starr, 
Porsch, Seed, 
& St. Geme 
III, 2016) 
pam 3’ Rev GCAAGCTTCCATATCGCTTTGGCTTTGC 
 
(Starr, 
Porsch, Seed, 
& St. Geme 
III, 2016) 
   
pamAB 
outside Rev 
GCTTTCGGAATGCTTGCGTACC 
 
This study 
pamA 
locator Rev 
GCAGGCTTGATACAGGTCTTTG 
 
This study 
pam inside 
For 
GCGACTGTTCCCAATACGATAG 
 
This study 
100 
 
pam inside 
Rev 
GCATCTGCTGCACGTTGCGTTG 
  
This study 
01 pamC 5’ 
For 
CGGCATTCCTTTGCATCACG This study 
181 pamC 5’ 
For 
ATCTTATCAATCTATCTGCCATGG This study 
pamC 3’ 
Rev 
AACGTTGCGACATAGCCTGTG This study 
pam Amp 
For 
ACGTGAATTCCGGCGCAAGATTTACAGC This study 
pamABC 
Amp Rev 
ACGTGGATCCTTTCGGGATATTGCGGTTGG This study 
pamABC 5’ 
Rev 
ACGTGGTACCACCTTCTGGTCGCTGAAATG This study 
pamABC 3’ 
For 
ACGTGGATCCCTATGTCGCAACGTTTGATAGG 
 
This study 
pamABC 3’ 
Rev 
ACGTAAGCTTGAATGTTGTCCAGCGCAATC 
 
This study 
pamDE 5’ 
For 
ACGTGAATTCTCGTGCTTATGCGCTGTTGC 
 
This study 
pamDE 5’ 
Rev 
ACGTGGTACCTTTCGGGATATTGCGGTTGG This study 
pamD For ATTTGGCTTCGCGTGTTG This study 
pamE Rev GGCGTGCCAAATTGAATC This study 
 
4.2.5 Serum bactericidal assays 
K. kingae strains were grown at 37°C with 5% CO2 on chocolate agar plates and 
then resuspended in PBS containing 0.1% gelatin (PBS-G). E. coli strains were grown on 
LB agar or shaking at 250 rpm in LB broth supplemented with 100 µg/ml ampicillin at 
37°C to OD600 0.8. Samples were diluted in PBS-G to obtain a final inoculum of 
approximately 4.0 x 103 cfu/0.1 ml. The respective inocula were mixed with pooled NHS 
(Immucor, Norcross, GA) or HI-NHS (prepared by incubating NHS at 56°C for 20 min) 
diluted in PBS-G, as appropriate, and incubated for various time points at 37°C with 5% 
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CO2. Serial dilutions of the inoculum and reaction samples were plated on chocolate agar 
plates and incubated overnight at 37°C with 5% CO2 to determine cfu counts (limit of 
detection for plating: 20 cfu).  
4.2.6 Statistical analysis 
Statistical analyses were performed with GraphPad Prism (version 7.0a) software 
for Mac (GraphPad Software, San Diego, CA), where a P value of <0.05 was considered 
statistically significant. The specific statistical tests used for each experiment are specified 
in the figure legends.  
4.3 Results 
4.3.1 Exopolysaccharide purification and visualization 
In order to extract and co-purify the polysaccharide capsule and exopolysaccharide, 
we collected bacterial supernatants from K. kingae strains KK01, KK01csaA, KK01pam, 
and KK01csaApam in 5 ml PBS. After concentration and proteinase K treatment, 
supernatants were separated on 7.5% SDS-PAGE gels (Fig. 18). The polysaccharide 
capsule from the surface of strains KK01 and KK01pam stained prominently with silver 
stain and Alcian blue reagents (Fig. 18), as demonstrated previously (Starr et al., 2013). 
The exopolysaccharide capsule from the surface of strains KK01 and KK01csaA stained 
prominently with silver stain but did not stain with Alcian blue (Fig. 18, data not shown). 
The supernatant from strain KK01csaApam failed to stain with either silver stain or Alcian 
blue reagents, as expected (Fig. 18).  
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Figure 18: Silver and Alcian blue staining of K. kingae surface polysaccharides 
present in bacterial supernatants.  
 
Samples were proteinase K treated and resolved on a 7.5% SDS-PAGE gel. Lane 1, 
protein ladder, molecular sizes in kDa; lane 2, strain KK01; lane 3, strain KK01csaA; 
lane 4, strain KK01pam; lane 5, strain KK01csaApam.  
 
4.3.2 KK01 pamABC is sufficient for serum resistance. 
 
Previous work determined that expression of pamABC from K. kingae clinical 
isolate PYKK181 in E. coli was sufficient for inhibiting biofilm formation (Bendaoud et 
al., 2011). To determine whether pamD and pamE were necessary for exopolysaccharide-
mediated serum resistance, we performed serum bactericidal assays using human serum. 
We deleted the entire pam locus (pamABCDE), or portions of the pam locus (pamABC or 
pamDE) in either strain KK01 or strain KK01csaA.  Inocula of 1.0 x 103 cfu were incubated 
for 1 hr with 50% human serum (Fig. 19), using strain KK01csaApam (containing a 
deletion of pamABCDE) as a serum-sensitive control. To assess serum sensitivity, a 
survival ratio was calculated, dividing the number of cfu recovered from NHS by the 
number of cfu recovered from HI-NHS.  
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Figure 19: Deletion of pamD and pamE does not affect K. kingae serum resistance in 
the absence of capsule.  
K. kingae strains KK01, KK01pam, KK01csaApam, KK01pamABC, 
KK01csaApamABC, KK01pamDE, and KK01csaApamDE were incubated with 50% 
NHS or 50% HI-NHS for 1 h. The survival ratio was calculated by dividing the NHS 
CFU counts by the HI-NHS CFU counts. A total of three biological replicates were 
performed (n = 3). Statistical significance was determined with an unpaired Student’s 
t test, and the error bars represent the standard error of the mean. *, P < 0.05.  
Deletion of pamABC or pamDE resulted in no growth defects on solid agar and had 
no effect on survival in the presence of 50% HI-NHS. Survival in 50% NHS by strains 
KK01pam, KK01pamABC, KK01pamDE, and KK01csaApamDE was not significantly 
different from the survival of wild-type strain KK01 (Fig. 19). In contrast, survival in 50% 
NHS by strains KK01csaApam and KK01csaApamABC was markedly reduced, with a 
survival ratio of ~0.40 (P < 0.05, Fig. 19).  
To further confirm that the KK01 pamABC genes promote serum resistance, we 
transformed E. coli strain DH5a with either an empty vector pUC19 plasmid or the 
pUC19pamABC plasmid. Due to the sensitivity to serum of strain DH5a, the serum 
resistance assays were performed by incubating DH5a derivatives with 2% human serum 
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for 30 min (Fig. 20). Five individual transformants harboring the pUC19pamABC plasmid 
were selected and assessed for changes in serum resistance, using DH5a/pUC19 as a 
serum-sensitive control. We observe in our preliminary data (n=2) that the survival ratio 
of DH5a/pUC19 in 2% NHS was ~0.18 (Fig. 20). In contrast, the survival ratio of 
DH5a/pUC19pamABC clones 1-3 in 2% NHS was much higher, between 0.55-0.70 (Fig. 
20). The survival ratio of DH5a/pUC19pamABC clones 4 and 5 in 2% NHS was 
moderately increased, approximately ~0.40 (Fig. 20). 
 
Figure 20: Expression of the KK01 pamABC genes in serum-sensitive E. coli increases 
serum resistance.  
E. coli strains DH5a/pUC19 (Vector) and DH5a/pUC19pamABC were incubated with 
2% NHS or 2% HI-NHS for 30 min. The survival ratio was calculated by dividing the 
NHS CFU counts by the HI-NHS CFU counts. A total of three biological replicates 
were performed (n = 2).  
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So far, these results establish that the pamABC genes are sufficient to promote 
serum resistance and confirm that pamD and pamE are not critical for exopolysaccharide-
mediated serum resistance in K. kingae and E. coli. 
4.3.3 Transcriptional analysis of KK01 pam locus. 
To determine expression of polycistronic transcripts in the exopolysaccharide 
biosynthesis locus, the transcription of K. kingae strain KK01 pamA, pamB, pamC, pamD, 
and pamE was assessed by RT-PCR. We performed RT-PCR from K. kingae KK01 cDNA 
using three forward primers that fall within the pamA, pamC, or pamD open reading frames 
(ORF) and four reverse primers within the pamB, pamC, pamD, or pamE ORF (Fig. 21A). 
Using Virtual Footprint analysis, predicted promoters were upstream of the pamA and 
pamD genes; no terminator sequences were detected within the pamABCDE locus (Münch 
et al., 2005). We detected amplicons of the expected size when using the specific primers 
for the contiguous genes pamAB, pamABC, pamCDE, pamCD, and pamDE (Fig. 21B-D). 
Conversely, amplicons were less abundant when using specific primers for the contiguous 
genes pamABCD and pamABCDE (Fig. 21B, C). 
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Figure 21: Transcription and polycistronic mRNA of pamABCDE locus in K. kingae 
strain KK01. 
 
Genomic structure of K. kingae pamABCDE genes and surrounding genes (A). 
Specific primers for RT-PCR designed to amplify PCR products are shown in arrows 
(forward primers, red; reverse primers, black). Polycistronic mRNA PCR products 
for pamAB, pamABC, pamABCDE, (B) pamABCDE, pamDE, (C), pamCD, and 
pamCDE (D). Lane 1, genomic DNA; Lane 2, cDNA; Lane 3, no reverse transcriptase 
(RT).  
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4.3.4 The type 1 and type 2 exopolysaccharides are associated with two 
distinct PamC proteins. 
Previous work determined that the septic arthritis clinical isolate KK01 expresses a 
à5)-β-Galf-(1à galactan homopolymer designated as a type 1 exopolysaccharide, 
whereas the bacteremia clinical isolate PYKK181 expresses a à3)-β-Galf-(1à5)-β-Galf-
(1à galactan homopolymer designated as a type 2 exopolysaccharide. To determine 
whether the differences in polymer linkages were due to genes present in the pam locus, 
we performed amino acid sequence alignments to compare the percent identity and 
similarity of the predicted PamA, PamB, PamC, PamD, and PamE proteins across the two 
K. kingae strains. This comparison revealed a lower percent identity and similarity between 
PamC alleles relative to the other proteins encoded by the pamABCDE locus, with an 
overall identity of 85% and a similarity of 91% (Fig. 22). The identity and similarity of 
PamA and PamB between strains was 99% (Fig. 22), the identity and similarity of PamD 
between strains was 100% (Fig. 22), and the identity and similarity of PamE between 
strains was 98% (Fig. 22).  
 
Figure 22: Comparison of the predicted protein products of the pam genes in K. kingae 
strains KK01 and PYKK181.  
 
Genomic organization of the pamABCDE loci in K. kingae strains KK01 (top) and 
PYKK181 (bottom). The light blue boxes highlight the identity and similarity based 
on amino acid sequence alignments of the predicted PamA, PamB, PamC, PamD, and 
PamE proteins (center); one number is denoted if the percent identity and similarity 
are the same.   
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Based on BLAST analyses, PamC is a predicted galactofuranosyl transferase, with 
potential to create linkages in polymer chains. Further analysis of the 592 amino acid PamC 
protein revealed a 146-amino acid stretch with relatively low identity (46%) and low 
similarity (67%) when comparing strain KK01 to strain PYKK181 (Fig. 23). Of the 55 
non-synonymous amino acid changes between strain KK01 PamC and strain PYKK181 
PamC, 48 were present in this 146-amino acid stretch of low homology (Fig. 23). These 
results suggest that PamC is the molecular determinant of exopolysaccharide diversity in 
K. kingae clinical isolates.  
 
Figure 23: Comparison of PamC across K. kingae strains KK01 and PYKK181.  
 
Schematic highlighting a region of low identity and similarity between KK01 PamC 
(blue) and PYKK181 PamC (red) (A). The light blue boxes highlight the identity and 
similarity between the full-length PamC proteins (A) and the 146-amino acid PamC 
fragments (B). Predicted amino acid sequence alignment of KK01 PamC (top) and 
PYKK181 PamC (bottom) highlighting the region with the lowest amount of 
homology (pink) (C).  
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4.3.5 pamC1 is predominant in clinical isolates of K. kingae. 
To determine the presence of the KK01 pamC allele (pamC1) or the PYKK181 
pamC allele (pamC2) in K. kingae clinical isolates, we designed allele-specific forward 
primers that anneal within the variable region of the pamC gene and a reverse primer that 
anneals within a conserved region of the pamC gene, producing allele-specific amplicons 
(Fig. 24A). PCR amplification of genomic DNA from K. kingae strains KK01, PYKK181, 
and KK01pam confirmed primer specificity to either the pamC1 or pamC2 allele (Fig. 
24B).  
 
Figure 24: K. kingae pamC allele PCR-typing method. 
 
Illustration of pamC alleles of K. kingae strains KK01 and PYKK181 highlighting the 
variable region in pamC1 (blue) and pamC2 (red) (A). Specific primers designed are 
shown in arrows (allele-specific forward primer, blue or red; conserved reverse 
primer, black).  PCR amplification of strains KK01pam, KK01, and PYKK181 using 
the pamC1-specific forward primer (top) or the pamC2-specific forward primer 
(bottom). Lane 1, DNA ladder; Lane 2, KK01pam; Lane 3, KK01; Lane 4, PYKK181.  
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Using the pamC allele PCR-typing method, we screened a collection of 24 clinical 
isolates for the presence of the pamC1 or pamC2 allele. The 24 clinical isolates represent 
14 sequence types based on multilocus sequence typing; 12 of the 14 sequence types are 
clustered into seven sequence type complexes (two of the sequence types represented do 
not fall into a sequence type complex) (Basmaci et al., 2014). Additionally, based on 
previous PFGE analysis, the clinical isolates represent 11 PFGE clonal groups (A, B, C F, 
H, K, N, P, V, and ϑ), including the five major clonal groups that account for >72% of 
invasive disease isolates (B, H, K, N, and P) (Amit et al., 2012; Starr, Porsch, Seed, Heiss, 
et al., 2016).  The cohort represents 12 strains from healthy carriers and 12 strains from 
patients with invasive disease, including bacteremia (5), septic arthritis (4), endocarditis 
(2), and osteomyelitis (1) (Basmaci et al., 2014).  
Amplicons were detected in all of the clinical isolates screened for one of the two 
pamC alleles (Fig. 25). The pamC1 allele was predominant among clinical isolates, present 
in 87.5% (21 of 24) of these strains (Fig. 25). The pamC2 allele was present in the other 
three clinical isolates screened (3 of 24, 12.5%) (Fig. 25). All three clinical isolates 
containing the pamC2 allele, K. kingae strains CC254, KK242, and Sch1614, fall within 
the same sequence type as strain PYKK181.  These data suggest that the type 1 
exopolysaccharide is the predominant exopolysaccharide present in K. kingae clinical 
isolates. No significant associations between exopolysaccharide type and clinical 
presentation were identified. Clinical isolates present in this study had been examined 
previously for capsule type (Starr, Porsch, Seed, Heiss, et al., 2016); however, no 
significant associations between exopolysaccharide type and capsule type were found.  
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Figure 25: PCR screening of a diverse cohort of K. kingae clinical isolates. 
 
PCR amplification of genomic DNA from K. kingae strains using the pamC1-specific 
forward primer (top) or the pamC2-specific forward primer (bottom). K. kingae 
strains KK01pam, KK01, and PYKK181 were used as controls. Color blocks above 
image represent clinical isolates present in a similar sequence type (red or purple) or 
sequence type complex (pink, orange, yellow, blue, green, sky, or navy). Lane 1, 
ATCC 23330; Lane 2, BB060; Lane 3, AA046; Lane 4, KK86; Lane 5, KK145; Lane 
6, KK12; Lane 7, KK136; Lane 8, KK83; Lane 9, BB012; Lane 10, KK142; Lane 11, 
KK98; Lane 12, KK164; Lane 13, KK144; Lane 14, KK190; Lane 15, CC254; Lane 
16, KK242; Lane 17, Sch1614; Lane 18, KKBB114 ; Lane 19, KK245; Lane 20, 
EE160; Lane 21, KK247; Lane 22, KK141; Lane 23, AA068; Lane 24, KK113. 
 
4.3.6 pamC2 is present in PFGE V clinical isolates.  
To determine whether clinical isolates within the same PFGE group as K. kingae 
strain PYKK181 possess the pamC2 allele, we used the pamC allele PCR-typing method 
to screen a collection of six clinical isolates present within the PFGE V or ϑ group. The 
cohort was comprised of two healthy carrier isolates and four invasive isolates, including 
isolated associated with bacteremia (2) and septic arthritis (2). The pamC1 allele was 
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present in 0% (0 of 6) of all clinical isolates screened (Fig. 26). The pamC2 allele was 
present in 100% (6 of 6) of all clinical isolates screened (Fig. 26). These results suggest 
that the pamC2 allele may be restricted to a distinct set of clinical isolates. Interestingly, 
all clinical isolates within these two PFGE groups express a type b polysaccharide capsule; 
however, based on Fig. 25, clinical isolates that produce a type b capsule may contain either 
the pamC1 or pamC2 allele.  
 
 
Figure 26: PCR screening of PFGE V K. kingae clinical isolates.  
 
PCR amplification of K. kingae strains using the pamC1-specific forward primer (top) 
or the pamC2-specific forward primer (bottom). K. kingae strains KK01pam, KK01, 
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and PYKK181 were used as controls. Lane 1, CC254; Lane 2, KK242; Lane 3, 
KK430; Lane 4, KK143; Lane 5, KK405; Lane 6, Sch1614.  
 
4.3.7 Both type 1 and type 2 exopolysaccharides confer serum 
resistance.   
To determine whether the type 2 exopolysaccharide also confers serum resistance 
in the absence of the polysaccharide capsule, we performed serum bactericidal assays using 
derivatives of K. kingae strain KK143, a septic arthritis clinical isolate producing a type b 
capsule and possessing the pamC2 allele. Unlike K. kingae strain PYKK181, K. kingae 
strain KK143 was amenable to genetic manipulation. Serum bactericidal assays were 
performed using strain KK143, strain KK143csb (a capsule-deficient mutant lacking the 
csbABC capsule synthesis locus), strain KK143pam (an exopolysaccharide-deficient 
mutant lacking the pamABCDE galactan exopolysaccharide synthesis operon), and strain 
KK143 csbpam (a double mutant lacking both capsule and exopolysaccharide synthesis 
genes). Assays were performed using 50% serum for 1 hr, and strains KK01, KK01csaA, 
KK01pam, and KK01csaApam were used as controls (Fig. 27A). Deletion of csb, pam, or 
both csb and pam resulted in no growth defects on solid agar and had no effect on survival 
in the presence of 50% HI-NHS. Survival in 50% NHS of strains KK143csb and 
KK143pam was not significantly different from the survival of wild-type strain KK143 
(Fig. 27B). In contrast, survival in 50% NHS by strain KK143csbpam was markedly 
reduced, with a survival ratio of less than 0.35 (P < 0.05, Fig. 27B).  
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Figure 27: The type 2 exopolysaccharide promotes serum resistance for K. kingae 
strain KK143.  
K. kingae strains KK01, KK01csaA, KK01pam, KK01csaApam, (B) KK143, 
KK143csb, KK143pam, and KK143csbpam (B) were incubated with 50% NHS or 
50% HI-NHS for 1 h. The survival ratio was calculated by dividing the NHS CFU 
counts by the HI-NHS CFU counts. A total of three biological replicates were 
performed (n = 3). Statistical significance was determined with an unpaired Student’s 
t test, and the error bars represent the standard error of the mean. *, P < 0.05. 
 
These results establish that in the absence of the polysaccharide capsule, the type 2 
exopolysaccharide is critical for survival in the presence of human serum, similar to 
observations with the type 1 exopolysaccharide. 
4.4 Discussion 
Polysaccharide-conjugate vaccines against Haemophilus influenzae, Neisseria 
meningitidis, and Streptococcus pneumoniae have provided long-lived protection, 
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reflecting stimulation of robust immune responses in infants (Goldblatt, 2000; Hyams et 
al., 2010; Moxon & Kroll, 1988; Swartley et al., 1997). Polysaccharide-conjugate vaccine 
design is typically guided by polysaccharide capsule diversity and correlation with invasive 
disease (Goldblatt, 2000). Analyses of a large collection of K. kingae clinical isolates 
revealed four distinct capsule structures and capsule biosynthesis loci, two of which 
account for >95% of invasive disease cases (Porsch et al., 2017; Starr, Porsch, Seed, Heiss, 
et al., 2016). Identification of the polysaccharide capsule led to the discovery of the 
exopolysaccharide, which has a distinct polymer structure separate from the polysaccharide 
capsule (Starr et al., 2013). In this study, we hoped to enhance understanding of the 
exopolysaccharides produced by K. kingae to better evaluate the potential of this factor as 
a vaccine candidate. 
Previous work from Bendaoud et al. utilized an inducible plasmid containing the 
pamABC locus from K. kingae strain PYKK181 in E. coli and demonstrated 
exopolysaccharide production and anti-biofilm properties (Bendaoud et al., 2011). Using a 
high copy number plasmid, we were able to demonstrate that expression of the strain KK01 
pamABC genes in E. coli promoted serum resistance, further confirming the importance of 
the exopolysaccharide in preventing complement-mediated lysis.  It is interesting to note 
that expression of the pamABC biosynthesis locus alone was sufficient for biofilm dispersal 
and serum resistance in E. coli, unlike the K. kingae polysaccharide capsule biosynthesis 
locus, which requires additional genes necessary for lipidation and capsule export 
(Bendaoud et al., 2011; Starr, Porsch, Seed, & St. Geme III, 2016).  
116 
 
Based on previous work and data from this study, PamD and PamE are not essential 
for exopolysaccharide biosynthesis, serum resistance, or biofilm dispersal (Bendaoud et 
al., 2011). Based on BLAST analyses, PamD and PamE are predicted putative 
glycosyltransferases. There is a predicted promoter binding site upstream of pamD, 
suggesting that pamD and pamE are separate from the pam exopolysaccharide biosynthesis 
locus. Unpublished data suggest that pamD and pamE affect K. kingae lipopolysaccharide 
(LPS) biosynthesis; however, it is unclear to what extent. Deletion of the pamABC locus 
did not visibly alter the LPS migration pattern, providing further evidence for distinct roles 
for the pamABC and pamDE genes (unpublished data). In ongoing studies, LPS 
purification and analysis will clarify the role of the pamD and pamE genes. 
Previous descriptions of the pam loci between K. kingae strains KK01 and 
PYKK181 noted high homology within the pamABCDE gene cluster; however, individual 
predicted amino acid sequence alignments of the five gene products revealed significant 
differences in the pamC products, suggesting that these gene products may be the 
molecular determinant of exopolysaccharide diversity. PCR-typing of the pamC alleles 
identified the pamC1 allele (type 1 exopolysaccharide) as predominant in the clinical 
isolates screened; although 11 PFGE clonal groups were represented, expanding our 
screening to a larger collection of isolates would provide a broader view of 
exopolysaccharide diversity . Interestingly, the pamC2 allele was predominant in the PFGE 
V clonal group. The PFGE V clonal group contained both carrier and invasive isolates with 
the pamC2 allele. Despite the lack of correlation between clinical presentation and 
exopolysaccharide type, use of the infant rat infection model may provide better insight to 
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differences in exopolysaccharide virulence properties in vivo. Further genetic manipulation 
is needed to confirm the function and properties of the two exopolysaccharide types and 
pamC alleles.  
The lack of cross-protection against antigenically distinct, encapsulated strains is a 
limitation of capsule-conjugate vaccines. Recently through the use of genomic sequencing, 
outer membrane proteins have been targeted as vaccine antigens in a variety of pathogens 
due to the conservation across strains (Etz et al., 2002; Pizza et al., 2000; Tan, Carlone, & 
Borrow, 2010; Wizemann et al., 2001). We demonstrate the presence of only two 
exopolysaccharide loci in K. kingae strains, with a majority of clinical isolates containing 
the type 1 exopolysaccharide locus, thus providing further evidence of the 
exopolysaccharide as an attractive vaccine candidate.   
The type 1 exopolysaccharide had been previously described as promoting K. 
kingae survival in human serum. Through the generation of surface polysaccharide mutants 
in K. kingae strain KK143, we were able to confirm that the type 2 exopolysaccharide 
exhibits similar properties. Exopolysaccharide pam swap constructs will be created to 
further confirm the galactofuranosyl transferase activity of pamC and to express the type 1 
and type 2 exopolysaccharides in an isogenic background for functional analyses in future 
experiments. 
To summarize, in this study we have established a SDS-PAGE staining protocol 
for visualization of co-purified surface polysaccharides and a pamC PCR-typing method. 
Analyses of the pam loci confirmed that pamABC is sufficient to promote serum resistance 
in both K. kingae as well as in E. coli. PCR-typing allowed us to determine the level of 
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diversity in the pamC allele across a collection of 27 K. kingae clinical isolates and confirm 
the presence of only two pamC alleles thus far. We were able to demonstrate that the type 
2 exopolysaccharide also functions to protect K. kingae against complement-mediated 
lysis. Future studies will focus on exopolysaccharide antigenicity and in vivo infection 
studies.  
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5. Future Directions 
5.1 Conclusion 
K. kingae displays high levels of resistance to innate immune components, 
specifically to complement- and neutrophil-mediated killing. The data presented in 
Chapters 2 and 3 demonstrate the significance of surface polysaccharides (the 
polysaccharide capsule and exopolysaccharide) in K. kingae immune evasion and virulence 
in vivo. Chapter 4 delves into the biosynthesis locus of the exopolysaccharide and explores 
the diversity of the exopolysaccharide present in K. kingae clinical isolates. The future 
directions and experimental approaches outlined below will identify and characterize other 
determinants of innate immune evasion in K. kingae. Moreover, we will investigate the 
multi-faceted functions of the K. kingae surface polysaccharides in immune evasion and 
begin to provide better insight into polysaccharide diversity and its contribution to K. 
kingae pathogenicity.  
5.2 Evaluate the impact of polysaccharide capsule diversity on immune 
evasion 
Capsule production by invasive pathogens promotes host survival by inhibiting 
complement activation and neutrophil recognition (Beiter et al., 2008; Campos et al., 2004; 
Hallström & Riesbeck, 2010; Hyams et al., 2010; Lambris et al., 2008; Wartha et al., 2007). 
Many species of bacteria express multiple different capsule serotypes, and in some cases a 
specific capsule type is associated with invasive disease potential, as is the case with H. 
influenzae serotype b capsule (Cochi, Broome, & Hightower, 1985) and Klebsiella 
pneumoniae capsule types K1 and K2 (Mizuta et al., 1983; Paczosa & Mecsas, 2016).  K. 
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kingae clinical isolates can be classified into four distinct capsule types (types a, b, c, and 
d) (Starr, Porsch, Seed, Heiss, et al., 2016). Strains expressing the type a and type b capsule 
account for >95% of invasive disease isolates (Porsch et al., 2017; Starr, Porsch, Seed, 
Heiss, et al., 2016), suggesting that the distinct capsule composition may play a role in the 
pathogenicity of K. kingae. 
As previously shown in Chapters 2 and 3, K. kingae strain KK01 expresses a type 
a polysaccharide capsule that protects K. kingae against complement- and neutrophil-
mediated killing (Muñoz et al., 2018). Furthermore, isogenic derivatives of strain 
KK01pam expressing one of the four capsule types were associated with a serum survival 
ratio similar to the serum survival ratio for strain KK01 (the parental strain) (Muñoz et al., 
2018). To assess whether the four capsule types differentially protect K. kingae against 
neutrophil-mediated killing, we performed neutrophil killing assays on isogenic derivatives 
of strain KK01pam expressing either capsule type a (strain KK01Swapcsapam), capsule 
type b (strain KK01Swapcsbpam), capsule type c (strain KK01Swapcscpam), or capsule 
type d (strain KK01Swapcsdpam). The survival of strains KK01pam, KK01pamSwapcsa, 
KK01pamSwapcsb, KK01pamSwapcsd was not affected at an MOI of 0.1 in the presence 
of neutrophils with 1% HSA or 1% NHS (Fig. 28A-C, E). The survival of strain 
KK01pamSwapcsc was slightly affected at an MOI of 0.1 in the presence of neutrophils 
with 1% NHS (Fig. 28D). As expected, survival of strain KK01pamSwapEmpty was 
significantly decreased at an MOI of 0.1 in the presence of neutrophils with 1% HSA and 
1% NHS (Fig. 28F). These data suggest that the presence of any of the four naturally 
occurring K. kingae capsule type is adequate in serving a protective role for K. kingae strain 
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KK01 under in vitro serum and neutrophil experiments. Future studies will investigate the 
slight changes in neutrophil sensitivity when the type c capsule is expressed in the 
KK01Swap background.  
 
 
Figure 28: The four distinct capsule types of K. kingae promote neutrophil survival 
in isogenic strain derivatives.  
 
K. kingae strain KK01pam (A), or isogenic derivatives of strain KK01pam expressing 
either capsule type a (Swapcsapam) (B), capsule type b (Swapcsbpam) (C), capsule 
type c (Swapcscpam) (D), capsule type d (Swapcsdpam) (E), or an empty cassette 
(SwapEmptypam) (F) were incubated with (white bars) or without (colored bars) 
neutrophils in the presence of 1% HSA or 1% NHS at an MOI of 0.1. The percent 
survival was calculated by dividing the cfu counts by the inoculum. Statistical 
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significance was determined using two-way analysis of variance and the Tukey post 
hoc test. The error bars represent the SEM of 3 independent experiments. *P <0.05; 
**P <0.01; ***P <0.001. 
 
Given the correlation between K. kingae capsule type and clinical presentation, we 
are interested in elucidating the virulence phenotype of capsule isogenic derivatives in vivo. 
To examine the virulence potential of the distinct K. kingae capsule types, we will use a 
previously described juvenile rat infection protocol (Starr, Porsch, Seed, & St. Geme III, 
2016). Briefly, five-day-old Sprague-Dawley rat pups will be injected via the 
intraperitoneal (i.p.) route with KK01 and KK01pam isogenic capsule swap strains. 
Morbidity and mortality will be monitored over a five-day period. We hypothesize that the 
K. kingae isogenic derivatives expressing either capsule type a or capsule type b will be 
more virulent in an in vivo infant rat infection model than isogenic derivatives expressing 
either capsule type c or capsule type d.  
Anti-capsular antibodies promote opsonization and lead to efficient complement 
and neutrophil activation as previously demonstrated in H. influenzae and K. pneumoniae 
(Jacob Amir, Liang, & Granoff, 1990; Anderson R. B., Jr.; Smith, D. H., 1972; Johnston, 
Anderson, Rosen, & Smith, 1973; Kobayashi et al., 2018). Currently, antisera against 
purified K. kingae capsular material conjugated to an immunogenic carrier protein is being 
generated in guinea pigs. ELISA analyses demonstrate the specificity of the K. kingae anti-
capsule antibodies to their respective capsule type (data not shown). To determine whether 
K. kingae anti-capsule antibodies enhance killing of encapsulated K. kingae, we will 
perform serum resistance and neutrophil-killing assays using capsule isogenic derivative 
strains in the presence of anti-capsule antibodies generated against the type a, b, c, or d 
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capsule. We predict that preincubation with anti-capsule antibodies will promote 
complement and neutrophil activation and enhance killing of encapsulated K. kingae 
strains. Additionally, in vivo administration of anti-capsule antibodies will be used in the 
juvenile rat infection model as a passive immunization strategy against K. kingae infection. 
We hypothesize that passive immunization will lead to attenuation of encapsulated K. 
kingae strains in our in vivo model.  
In H. influenzae and K. pneumoniae, capsule overproduction is associated with 
disease and hypervirulent strains (Dorman, Feltwell, Goulding, Parkhill, & Short, 2018; 
Noel et al., 1996, 1992; Paczosa & Mecsas, 2016; Shon, Bajwa, & Russo, 2013; Swift et 
al., 1991). Earlier studies utilized atomic force microscopy to determine the average depth 
of the K. kingae type a capsule in strain KK01 (Kern et al., 2017). Evaluation of KK01 
capsule isogenic derivative strains as well as clinical isolates from both invasive and carrier 
strains using atomic force microscopy may provide valuable insight into differences in 
capsule production and expression between the four capsule types and across a diverse 
cohort of K. kingae strains.  
5.3 Binding of complement regulators and contribution to K. kingae 
serum resistance 
 
Complement activation is highly inflammatory and can cause host tissue damage; 
therefore, the three complement pathways are highly regulated through a variety of effector 
proteins to prevent aberrant activation (Zipfel & Skerka, 2009). So far, over 20 soluble and 
surface-bound effector proteins have been identified, including C4b-binding protein 
(C4BP), factor H, and vitronectin.  C4BP and factor H act as cofactors for factor I 
124 
 
recruitment; factor I mediates degradation of C4b and C3b (Blom et al., 2004a; Blom, 
Villoutreix, & Dahlbäck, 2004b; Józsi & Zipfel, 2008; Rodríguez de Córdoba, Esparza-
Gordillo, Goicoechea de Jorge, Lopez-Trascasa, & Sánchez-Corral, 2004).  Degradation 
of C4b and C3b accelerates the decay of C3 convertases, C4b2a and C3bBp, respectively. 
Vitronectin is present in plasma and considered an important component of the 
extracellular matrix; vitronectin functions to prevent insertion of the membrane attack 
complex into bacterial membranes (Preissner & Seiffert, 1998). Pathogenic bacteria can 
exploit complement regulation through the acquisition of these soluble effectors. N. 
meningitidis and N. gonorrhoeae (members of the Neisseriaceae family) bind factor H to 
prevent activation of the alternative pathway (Lewis et al., 2012; Ram, Sharma, et al., 
1998). We hypothesized that K. kingae, a member of the Neisseriaceae family, binds factor 
H, promoting survival of the bacterium even in the absence of surface polysaccharides.  
To investigate whether K. kingae binds complement regulator factor H, we 
performed flow cytometry assays to determine relative levels of factor H deposition on the 
K. kingae surface using human serum as a source for factor H. In comparison to E. coli 
strain DH5a, there was a significant increase in factor H deposition on the bacterial 
surfaces of K. kingae strains KK01, KK01csaA, KK01pam, and KK01csaApam when 
incubated with either 1% or 5% HI-NHS (Fig. 29). Interestingly, deletion of the 
exopolysaccharide biosynthesis locus, pam, led to a significant increase in factor H 
deposition, although it remains unknown as to why this occurs (Fig. 29). The data 
demonstrate that factor H is deposited on the surface of K. kingae and that presence of the 
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exopolysaccharide either hinders antibody recognition of surface-bound factor H or 
inhibits factor H binding. 
 
Figure 29: Complement regulator, factor H, is present on the K. kingae surface after 
serum incubation.  
 
Binding of factor H to the bacterial surface of K. kingae strains KK01, KK01csaA, 
KK01pam, KK01csaApam and E. coli strain DH5a was determined using flow 
cytometry. Cells were stained with propidium iodine (PI) prior to analysis; 30,000 
propidium iodine-positive events per biological replicate were analyzed, and a total 
of three biological replicates were performed (n = 3). The percentages represent 
events that registered as Alexa Fluor 488 positive (AF-488+). Dark red bars, 5% HI-
NHS; Red bars, 1% HI-NHS; gray bars, secondary antibody-only controls (these bars 
are negligible in size due to the low signal).  
 
Using protein blast alignment against K. kingae, we uncovered glycoprotein 2 
(GP2), which has predicted homology to the N. meningitidis factor H binding protein 
(FHBP). K. kingae GP2 is 21.2% identical and 34.2% similar to N. meningitidis FHBP and 
using Phyre2 structural analysis shows 18-27% identity to FHBP (Kelley, Mezulis, Yates, 
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Wass, & Sternberg, 2015). To investigate whether GP2 is necessary for factor H binding, 
we generated GP2-deletion strains in the K. kingae strains KK01, KK01csaA, KK01pam, 
and KK01csaApam. Using the KK01 GP2-deficient strains, we performed flow cytometry 
assays to determine relative levels of factor H deposition on the K. kingae bacterial surface 
s. There was no change in factor H deposition when GP2 was present or absent (data not 
shown). This result suggests that either GP2 is not necessary for factor H-binding or that 
K. kingae expresses additional surface structures that promote factor H deposition.  
To determine whether GP2 was necessary for K. kingae serum resistance, we 
performed serum bactericidal assays using GP2-deficient strains and KK01csaApam as a 
serum-sensitive control. No changes in the survival ratio were observed in the GP2-
deficient strains when compared to KK01 (data not shown). No further analyses were 
performed using the GP2-deficient strains.  
Unpublished data from the lab determined that the trimeric autotransporter, Knh, 
was necessary for adherence to vitronectin-coated plates. Vitronectin is present in human 
serum and is a regulator of the terminal complement pathway (Preissner & Seiffert, 1998). 
To determine the role of Knh in K. kingae serum resistance, we performed serum 
bactericidal assays using strains KK01, KK01csaApam, and Knh-deficient mutants. No 
changes in the survival ratio were observed in the Knh-deficient strains when compared to 
the parental strain (data not shown). To investigate whether Knh is necessary for factor H 
binding, we performed flow cytometry assays to determine relative levels of factor H 
deposition on the K. kingae surface in KK01 Knh-deficient strains. There was no change 
in factor H deposition when Knh was present or absent (Fig. 30). This result suggests that 
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either Knh is not necessary for factor H-binding or that K. kingae expresses additional 
surface structures that promote factor H deposition. Knh and GP2 double mutants have not 
been generated.  
 
Figure 30: Elimination of the trimeric autotransporter, Knh, does not affect factor 
H deposition. 
 
Binding of factor H to the bacterial surface of K. kingae strains KK01, KK01knh, 
KK01csaApam, and KK01csaApamknh was determined using flow cytometry. Cells 
were stained with propidium iodine (PI) prior to analysis; 30,000 propidium iodine-
positive events per biological replicate were analyzed, and a total of three biological 
replicates were performed (n = 3). The percentages represent events that registered 
as Alexa Fluor 488 positive (AF-488+). Red bars, 1% HI-NHS; gray bars, secondary 
antibody-only controls (these bars are negligible in size due to the low signal).  
 
 Future studies will determine whether vitronectin and C4BP are deposited on the 
bacterial surface of K. kingae using the previously described flow cytometry assays. 
Additionally, we will perform serum resistance assays using depleted serum to determine 
the necessity of factor H, C4BP, and vitronectin deposition for K. kingae survival in the 
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presence or absence of surface polysaccharides. While the loss of capsule and 
exopolysaccharide promotes activation of the classical pathway through antibody 
deposition, the deposition of factor H and vitronectin may inhibit the alternative and 
terminal pathways to promote a low level of survival as demonstrated in Ch. 2. We 
hypothesize that K. kingae will be less resistant to human serum when complement 
regulators have been depleted from the serum.  
5.4 Tn-seq analyses for additional K. kingae immune evasion factors 
5.4.1 Complement evasion    
Our previous work demonstrates that the elimination of both the capsule and 
exopolysaccharide resulted in reduced resistance to complement-mediated lysis (Ch. 2) 
(Muñoz et al., 2018). Interestingly, elimination of these surface polysaccharides did not 
completely render the K. kingae bacterium sensitive to human serum, suggesting that K. 
kingae employs additional factors to prevent membrane attack complex formation and 
complement-mediated lysis.  
To determine additional factors that mediate serum resistance in the absence of 
surface polysaccharides, we generated a K. kingae transposon (Tn) mutant library in strain 
KK01csaApam (Fig. 31A). The current mutant library contains ~42,000 random 
transposon mutants, an approximate 21x coverage of the K. kingae genome. Serum survival 
assays were performed using 1 x 107 bacteria from the pooled mutant library in 20% NHS 
or HI-NHS (Fig. 31B). Genomic DNA was recovered from four technical replicates in 
three separate experiments. In on-going experiments, we are processing purified genomic 
DNA for high-throughput sequencing, which will be used to identify transposon insertions 
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that are reduced or absent in the challenge condition (20% NHS). Candidate targets will be 
subjected to deletion and complementation to confirm the serum-sensitive phenotype.  
 
Figure 31: Schematic representation of Tn-seq screen for K. kingae survival in human 
serum. 
 
Generation of K. kingae mutant library by using the Himar transposase to introduce 
random transposon insertions into the K. kingae genome (A). Mutated DNA is then 
transformed back into K. kingae. Mutant library is challenged using 20% NHS or 
20% HI-NHS and recovered DNA is processed and mapped using Illumina 
sequencing (B). Figure adapted from (van Opijnen, Bodi, & Camilli, 2009) and 
(Langereis, 2014). 
 
5.4.2 Neutrophil evasion    
The previously generated transposon mutant library described in Ch. 5 sub-section 
5.4.1 may be utilized in neutrophil-killing assays to determine additional factors necessary 
for K. kingae neutrophil evasion in the absence of the polysaccharide capsule and 
exopolysaccharide. Tn-seq screens have been performed previously in nontypeable H. 
influenzae (NTHi) to elucidate LOS-modifying proteins that protect NTHi in the presence 
of neutrophils (Langereis & Weiser, 2014). Additionally, assays will be performed in the 
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absence or presence of human serum to identify candidate genes that prevent neutrophil-
mediated killing in the presence of serum opsonins. 
5.5 Determine mechanism of capsule inhibition of neutrophil ROS 
production 
  
Elimination of the K. kingae capsule stimulates a rapid and robust release of 
reactive oxygen species (ROS) by human neutrophils during K. kingae infection (Ch. 3). 
In the absence of the K. kingae polysaccharide capsule, increased neutrophil recognition of 
bacterial LPS may prompt TLR4 activation and subsequent ROS production. TLR4 is 
activated by LPS and upon activation recruits the NADPH-oxidase complex, Nox4 (Kaisho 
& Akira, 2006; Park et al., 2004; Qureshi et al., 1999). Nox4 is then able to generate ROS 
and promote proinflammatory cytokine expression (Ngkelo et al., 2012; Park et al., 2004). 
To determine whether TLR4 was activated by K. kingae, we performed a 
chemiluminescence bio-assay using a neutralizing rat IgG monoclonal antibody to human 
TLR4 (anti-TLR4) to inhibit the biological activity of TLR4; an isotype control for rat 
IgG1 was included as a negative control (Fig. 32, 33). LPS from Salmonella enterica 
serotype enteritidis was included as a positive control for TLR4 activation and ROS 
production by neutrophils (Fig. 32A). Preliminary data (n=1) suggest a slight reduction in 
ROS production during neutrophil incubation with strain KK01csaA in the presence of the 
anti-TLR4 antibody (Fig. 32C, 33B). No changes in ROS production were observed with 
strains KK01, KK01pam, and KK01csaApam in either 1% HSA or 1% NHS in the presence 
of the anti-TLR4 antibody (Fig. 32, 33). As previously demonstrated, the preliminary data 
suggest a marked increase in ROS production when neutrophils are incubated with strain 
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KK01csaApam (Fig. 32E, 33D). Currently, ongoing experiments are focused on improving 
K. kingae LPS purification and structural analysis. Future studies will use purified K. 
kingae LPS and polysaccharide capsule to determine changes in neutrophil TLR4 
activation.  
 
Figure 32: Detection of neutrophil TLR4 activation during K. kingae infection. 
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Salmonella enterica serotype enteritidis LPS (A) and K. kingae rtx mutant strains, 
KK01 (B), KK01csaA (C), KK01pam (D), and KK01csaApam (E) were incubated with 
human neutrophils at an MOI of 10 in the presence of 1% HSA. Assays were 
performed in the presence of 10µg/ml rat anti-TLR4 antibodies (triangles), 10µg/ml 
rat IgG1 antibody control (squares), or media alone (circles). Chemiluminescence was 
measured at 5-min intervals for 75 min for kinetic analysis. Gray plot points represent 
neutrophil-only control (A-E). Data represents an n=1.  
 
 
 
Figure 33: Detection of neutrophil TLR4 activation during K. kingae infection in the 
presence of serum opsonins.  
 
K. kingae rtx mutant strains, KK01 (A), KK01csaA (B), KK01pam (C), and 
KK01csaApam (D) were incubated with human neutrophils at an MOI of 10 in the 
presence of 1% NHS. Assays were performed in the presence of 10µg/ml rat anti-
TLR4 antibodies (triangles), 10µg/ml rat IgG1 antibody control (squares), or media 
alone (circles). Chemiluminescence was measured at 5-min intervals for 75 min for 
kinetic analysis. Gray plot points represent neutrophil-only control (A-E). Data 
represents an n=1.  
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5.6 Determine the mechanism by which exopolysaccharide inhibits 
neutrophil phagocytosis  
 K. kingae bacterial association to human neutrophils was significantly increased in 
the absence of the polysaccharide capsule (Ch. 3). Despite promoting neutrophil 
association, the loss of capsule alone did not significantly increase neutrophil uptake and 
phagocytosis (Ch. 3). Interestingly, elimination of both the capsule and exopolysaccharide 
led to an increase in intracellular bacteria, suggesting that the exopolysaccharide inhibited 
or delayed neutrophil uptake of associated bacteria (Ch. 3). We will perform live cell 
fluorescence microscopy to investigate interactions between neutrophils and various 
mutant strains of K. kingae KK01. To distinguish bacterial cells from neutrophils, we will 
stain each population prior to infection with the appropriate fluorescent cellular dye. We 
hypothesize that the exopolysaccharide may provide a physical barrier or blockage during 
bacterial uptake. Alternatively, the exopolysaccharide may play a direct role in phagocytic 
inhibition through interactions with neutrophil receptors. While the use of live cell 
fluorescence microscopy may not provide direct answers as to whether the 
exopolysaccharide is interacting with neutrophil receptors, visualization of neutrophil-
bacterial association will provide a better understanding of cellular dynamics during K. 
kingae infection.  
5.7 Effect of surface polysaccharides on cytokine expression and release 
Beyond clearing pathogenic bacteria through intracellular and extracellular 
mechanisms, neutrophils can release of a large subset of cytokines and chemokines upon 
recruitment (Mayadas, Cullere, & Lowell, 2014; Mócsai, 2013). Various neutrophil 
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receptors, including pathogen recognition receptors (PRR) as mentioned previously, 
trigger cytokine and chemokine production (Scapini et al., 2000; Tecchio et al., 2014).   
Given the differences in neutrophil activation upon infection with capsule-deficient 
K. kingae, ELISA assays will be performed to determine the secretion of IL-1a, IL-1b, IL-
6, TNFa, and IFNg following incubation of neutrophils with K. kingae in the presence or 
absence of serum opsonins. Additionally, we plan to determine proinflammatory and anti-
inflammatory cytokine transcript levels in infected neutrophils using qRT-PCR. Assays 
will be performed using wild type and K. kingae mutants lacking the capsule, 
exopolysaccharide, or both to establish how these surface polysaccharides influence 
neutrophil cytokine expression and secretion. In Ch. 3, we demonstrated a lack of 
neutrophil activation and neutrophil-mediated killing when the capsule was present. We 
hypothesize that expression of the K. kingae polysaccharide capsule inhibits or reduces 
cytokine release. As speculated in Ch. 5.5, we assume elimination of capsule leads to LPS 
exposure and recognition by TLR4, thus triggering ROS production and perhaps changing 
the cytokine profile.  
While the loss of exopolysaccharide alone did not render K. kingae sensitive to 
neutrophil-mediated killing, elimination of both surface polysaccharides promoted 
phagocytosis of K. kingae, suggesting that the exopolysaccharide may inhibit or prevent 
phagocytosis (Ch. 3). A reported galactan homopolysaccharide in Mycoplasma mycoides 
subsp. mycoides similar to the K. kingae exopolysaccharide binds TLR2 and promotes the 
production of anti-inflammatory cytokines (Totté et al., 2015). We hypothesize that the K. 
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kingae exopolysaccharide may interact with neutrophil receptor(s) and prompt changes in 
cytokine expression and secretion.  
5.8 Determine regulatory elements for polysaccharide capsule 
production 
A mariner transposon mutagenesis strategy was implemented to determine essential 
genes or loci for encapsulation of K. kingae strain KK01 (Starr, Porsch, Seed, & St. Geme 
III, 2016). Around 10,000 transposon mutants were screened for a non-mucoid phenotype, 
which is expected of non-encapsulated organisms (Starr, Porsch, Seed, & St. Geme III, 
2016). Through screening and bioinformatic approaches, capsule export, assembly, and 
biosynthesis genes were identified (ctrABCD operon, lipA, lipB, and csaA) (Starr, Porsch, 
Seed, & St. Geme III, 2016). Despite successfully identifying genes necessary for 
encapsulation, capsule regulatory components were absent from the transposon screen. 
Unfortunately, the non-mucoid phenotype was not suitable for identification of regulatory 
networks that alter the production and/or depth of the K. kingae capsule.  
Recently, Dorman et al. employed a density-TraDISort strategy in K. pneumoniae 
to determine genes that influence capsule production (Dorman et al., 2018). Density-
TraDISort combines density gradient centrifugation using varying percentages of Percoll 
with transposon insertion sequencing (Dorman et al., 2018). Our initial studies will 
determine migration patterns of wild-type KK01 and various KK01 capsule-mutant strains. 
We predict that optimization may be required to more accurately separate differentially 
encapsulated K. kingae bacteria. We will perform thiobarbituric acid reactivity assays as 
previously described to determine the amount of capsule present in each fraction and 
validate expected separation patterns (Starr, Porsch, Seed, & St. Geme III, 2016; Straus, 
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Lonon, Woods, & Garner, 1990; Warren, 1963). If K. kingae is amenable to density 
centrifugation, genomic DNA from strain KK01pam will be used for the generation of a 
transposon mutant library. Unlike K. pneumoniae, K. kingae strains express an 
exopolysaccharide that may alter the migration pattern of non-encapsulated K. kingae. The 
density-TraDISort strategy may be useful for identification of exopolysaccharide 
regulatory elements. However, the exopolysaccharide is secreted and not membrane-
anchored like the polysaccharide capsule. Therefore, separation of bacteria based on levels 
of exopolysaccharide release through centrifugation may not be plausible.  
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